Original Article
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
N Engl J Med 2005; 353:2433-2441December 8, 2005
- Abstract
Background
Recent reports suggest that the rate and severity of Clostridium difficile–associated disease in the United States are increasing and that the increase may be associated with the emergence of a new strain of C. difficile with increased virulence, resistance, or both.
Methods
A total of 187 C. difficile isolates were collected from eight health care facilities in six states (Georgia, Illinois, Maine, New Jersey, Oregon, and Pennsylvania) in which outbreaks of C. difficile–associated disease had occurred between 2000 and 2003. The isolates were characterized by restriction-endonuclease analysis (REA), pulsed-field gel electrophoresis (PFGE), and toxinotyping, and the results were compared with those from a database of more than 6000 isolates obtained before 2001. The polymerase chain reaction was used to detect the recently described binary toxin CDT and a deletion in the pathogenicity locus gene, tcdC, that might result in increased production of toxins A and B.
Results
Isolates that belonged to one REA group (BI) and had the same PFGE type (NAP1) were identified in specimens collected from patients at all eight facilities and accounted for at least half of the isolates from five facilities. REA group BI, which was first identified in 1984, was uncommon among isolates from the historic database (14 cases). Both historic and current (obtained since 2001) BI/NAP1 isolates were of toxinotype III, were positive for the binary toxin CDT, and contained an 18-bp tcdC deletion. Resistance to gatifloxacin and moxifloxacin was more common in current BI/NAP1 isolates than in non-BI/NAP1 isolates (100 percent vs. 42 percent, P<0.001), whereas the rate of resistance to clindamycin was the same in the two groups (79 percent). All of the current but none of the historic BI/NAP1 isolates were resistant to gatifloxacin and moxifloxacin (P<0.001).
Conclusions
A previously uncommon strain of C. difficile with variations in toxin genes has become more resistant to fluoroquinolones and has emerged as a cause of geographically dispersed outbreaks of C. difficile–associated disease.
Media in This Article
Figure 1
Major Genes in the Pathogenicity Locus (PaLoc) of Clostridium difficile and Relation to the Genes for Binary Toxin.Figure 2
Pulsed-Field Gel Electrophoresis Results and Dendrographic Analysis of a Sample of BI/NAP1 and Non-BI/NAP1 Isolates from Current Outbreaks of Clostridium difficile–Associated Disease and of Isolates from a Historic Database.Article Activity
- Article
Clostridium difficile is a gram-positive, anaerobic, spore-forming bacillus that can cause pseudomembranous colitis and other C. difficile–associated diseases. Studies during the 1970s showed that two toxins, A and B, were involved in the pathogenesis of C. difficile–associated disease.1-5 Transmission occurs primarily in health care facilities, where exposure to antimicrobial drugs (the major risk factor for C. difficile–associated disease) and environmental contamination by C. difficile spores are more common.6 Certain strains of C. difficile have a propensity to cause outbreaks, including multistate outbreaks in health care facilities.7 Because these outbreak-associated strains are resistant to certain antimicrobial agents, such as clindamycin, the use of such antimicrobial agents provides these strains with a selective advantage over strains that are not associated with outbreaks. Historically low rates of severe disease and death (3 percent or less) may have led to an underestimation of the importance of C. difficile–associated disease as a health care–associated infection8; however, each case of C. difficile–associated disease has been estimated to result in more than $3,600 in excess health care costs, and these costs may exceed $1 billion annually in the United States.9
Both the rate and the severity of C. difficile–associated disease may be increasing in U.S. health care facilities. An analysis of data from the National Nosocomial Infections Surveillance system identified an upward slope in C. difficile–associated disease rates from the late 1980s through 2001.10 Of greater concern is a reported increase of 26 percentage points between 2000 and 2001 in the proportion of patients discharged from nonfederal U.S. hospitals with C. difficile–associated disease listed as a diagnosis.11
Indications of the increased severity of C. difficile–associated disease include reports from the University of Pittsburgh Medical Center, where the incidence of the disease in 2000 and 2001 was nearly twice as high as in 1990 through 1999. Twenty-six patients with severe disease required colectomy, and 18 patients died.12-14 In addition, in the past two years, the Centers for Disease Control and Prevention (CDC) has received an increased number of reports from health care facilities of cases of severe C. difficile–associated disease that have resulted in admissions to intensive care units, colectomies, and deaths. These reports have been confirmed by a nationwide survey of infectious-disease physicians in the Emerging Infections Network of the Infectious Diseases Society of America, which found that approximately 39 percent of respondents noted an increase in the severity of cases of C. difficile–associated disease in their patient population.15
One explanation for an increase in both the rate and the severity of C. difficile–associated disease could be the emergence of an epidemic strain with increased virulence, antimicrobial resistance, or both. To examine this possibility, we characterized C. difficile isolates obtained from health care facilities that reported outbreaks from 2001 through 2003 and compared these isolates with historic isolates (obtained before 2001) with the use of strain typing, identification of genetic determinants of newly described virulence factors, and testing for antimicrobial susceptibility.
Methods
Health Care Facilities and Isolates from Patients
Isolates were collected from patients in eight health care facilities that had reported an outbreak of C. difficile–associated disease since 2001 to investigators at either the CDC or the Hines Veterans Affairs (VA) Hospital. These facilities were located in six states (Georgia, Illinois, Maine, New Jersey, Oregon, and Pennsylvania); all were acute care hospitals, except for one long-term care facility in Georgia that was associated with a VA hospital.16 The isolates were obtained from patients who had received a diagnosis of C. difficile–associated disease on the basis of clinical history (e.g., diarrhea with recent receipt of an antimicrobial drug) and a positive clinical laboratory test for C. difficile toxin (e.g., cytotoxin assay or enzyme immunoassay). Isolates from current (since 2001) outbreaks were compared with isolates from a historic (pre-2001) database of more than 6000 C. difficile isolates maintained by Hines VA investigators. The isolates in the historic database were collected during the period from 1984 through 1990; all isolates were extensively characterized by HindIII restriction-endonuclease analysis (REA) and linked to clinical and epidemiologic data.
Strain Typing
The isolates underwent REA typing and pulsed-field gel electrophoresis (PFGE), as previously described17,18; software from BioNumerics 3.5 (Applied Maths) was used to perform dendrographic analysis of the PFGE results. In addition, toxinotyping was performed according to the method of Rupnik et al., with modifications.19 Toxinotyping analyzes the restriction-fragment–length polymorphisms (RFLPs) of the genes encoding toxins A (tcdA) and B (tcdB), the surrounding regulatory genes (tcdC and tcdD), and a porin gene (tcdE) in a region of the C. difficile genome known as the pathogenicity locus (PaLoc) (Figure 1Figure 1
Major Genes in the Pathogenicity Locus (PaLoc) of Clostridium difficile and Relation to the Genes for Binary Toxin.). Because RFLP analysis of polymerase-chain-reaction (PCR) fragments A3 and B1 results in a pattern sufficient to identify most toxinotypes,19 we limited our analysis to these two fragments.Molecular Markers of Potentially Increased Virulence
In addition to the well-characterized A and B toxins, a binary toxin has been identified in about 6 percent of clinical C. difficile isolates obtained in the United States and Europe.20,21 The structure and function of this toxin (referred to as binary toxin CDT) are similar to those of other binary toxins, such as the iota toxin found in C. perfringens, and it is a suspected virulence factor in strains of C. difficile that carry the toxin.22 We detected the C. difficile binary toxin gene by using PCR for cdtB, which is located outside the PaLoc and encodes the beta subunit of the binary toxin (Figure 1).20
We also looked for deletions in tcdC by using PCR with the primers tcdc1 and tcdc2, which were synthesized at the CDC Core Facility on the basis of published sequences.23 The gene tcdC is located within the PaLoc downstream from the genes encoding toxins A and B, and it is transcribed in the opposite direction from these genes (Figure 1). The tcdC protein is thought to function as a negative regulator of the production of toxins A and B. Recently, multiple alleles of tcdC have been described that include different-sized deletions, point mutations, and in one case, a nonsense mutation, all of which would result in a truncated tcdC protein.23,24 It has been hypothesized that mutations in tcdC may result in a loss of negative regulatory function, leading to increased toxin production and virulence.23,24
Testing for Antimicrobial Susceptibility
Susceptibility to clindamycin and the fluoroquinolones (levofloxacin, gatifloxacin, and moxifloxacin) was determined with the use of E-test strips (AB Biodisk), and the results were interpreted according to standard criteria.25 Specific breakpoints for the interpretation of clindamycin-susceptibility results were available from the Clinical and Laboratory Standards Institute (CLSI; formerly the National Committee for Clinical Laboratory Standards).25 However, because no breakpoints have been set by the CLSI for C. difficile tested against these fluoroquinolones, the CLSI breakpoints for C. difficile tested against trovafloxacin were used. The validity of the trovafloxacin breakpoints was confirmed by identification of two distinct subpopulations in the distribution of minimum inhibitory concentrations (MICs) for apparently susceptible isolates, as compared with resistant isolates, tested against these fluoroquinolones; these subpopulations were demarcated by the trovafloxacin breakpoints. Quality control of antimicrobial-susceptibility testing was performed during each test run with the standard strains Enterococcus faecalis American Type Culture Collection (ATCC) 29212, Pseudomonas aeruginosa ATCC 27583, Bacteroides fragilis ATCC 25285, and B. thetaiotaomicron ATCC 29741.
Statistical Analysis
To compare the overall resistance patterns of current epidemic and nonepidemic isolates, a total of three (determined according to the availability of isolates) epidemic-strain (case) and three nonepidemic-strain (control) isolates, as determined by REA and PFGE, were randomly selected from each health care facility. Resistance was then compared by matched case–control analysis with the use of Epi Info software (version 6.02). This method was chosen to take into account possible geographic variation in resistance and to avoid bias resulting from outbreaks with a larger number of isolates. In contrast, we used Fisher's exact test and the StatCalc function of Epi Info software (version 6.02) to make an unmatched comparison between current and historic epidemic isolates. All P values are based on a two-tailed comparison.
Results
A total of 187 isolates were obtained from the eight health care facilities in which the outbreaks occurred. In each of the facilities, a strain composed of closely related isolates was identified by both PFGE and REA. This epidemic strain accounted for 50 percent or more of the isolates from five of the eight facilities (Table 1Table 1
Isolates of Clostridium difficile According to Health Care Facility and the Proportion of Isolates Belonging to the BI/NAP1 Strain.). The epidemic strain has been identified as belonging to REA group BI and North American PFGE type 1 (NAP1). Within this strain, characterized as BI/NAP1, the isolates have been further differentiated on the basis of minor differences in the band pattern into 14 REA subtypes, designated by numbers, in which at least 90 percent of the bands are identical.17 Similarly, several PFGE subtypes are included in the NAP1 designation. Five REA BI types (BI1 through BI5), dating back to 1984, were identified in the historic database. These represented 18 isolates obtained from 14 patients and consisted of 5 isolates of BI1 from 4 patients, 8 isolates of BI2 from 7 patients, 2 isolates of BI3 from 1 patient, 2 isolates of BI4 from 1 patient, and 1 isolate of BI5 from 1 patient.One isolate from each of the five REA BI types in the historic database was selected for further genetic testing, along with three BI/NAP1 and three non-BI/NAP1 current isolates from each health care facility. The PFGE results and the dendrogram of these representative isolates are shown in Figure 2Figure 2
Pulsed-Field Gel Electrophoresis Results and Dendrographic Analysis of a Sample of BI/NAP1 and Non-BI/NAP1 Isolates from Current Outbreaks of Clostridium difficile–Associated Disease and of Isolates from a Historic Database., along with the toxinotype, the status of binary CDT, and the status of a deletion in the tcdC gene. According to dendrographic analysis, 25 of 29 of the combined current and historic BI/NAP1 isolates (86 percent) were 90 percent or more related, and all were more than 80 percent related. In contrast to this close relatedness among BI/NAP1 isolates across a wide geographic area, relatively few non-BI/NAP1 isolates were more than 80 percent related. All of the BI/NAP1 isolates were of toxinotype III, were positive for binary toxin CDT, and had an 18-bp deletion in tcdC; these features were largely absent among non-BI/NAP1 isolates (Figure 2). Of the 24 non-BI/NAP1 isolates, 20 (83 percent) were toxinotype 0, none of which had binary toxin CDT or the tcdC deletion.Susceptibility testing was performed on the 3 current BI/NAP1 and non-BI/NAP1 isolates from each health care facility, as well as on the 14 patient BI isolates available from the historic database. Among current isolates (obtained after 2000), all BI/NAP1 and only a fraction of the non-BI/NAP1 isolates were resistant to gatifloxacin and moxifloxacin (Table 2Table 2
Resistance of Current BI/NAP1 Clostridium difficile Isolates, Current Non-BI/NAP1 Isolates, and Historic BI/NAP1 Isolates to Clindamycin and Fluoroquinolones.). Although both BI/NAP1 and non-BI/NAP1 isolates were largely resistant to clindamycin and levofloxacin, the MICs of levofloxacin were higher for BI/NAP1 isolates as a group (Figure 3Figure 3
Distribution of Minimum Inhibitory Concentrations of Levofloxacin for Current (Obtained after 2000) BI/NAP1 and Non-BI/NAP1 Clostridium difficile Isolates.). All current BI/NAP1 isolates and no historic isolates (obtained before 2001) were resistant to gatifloxacin and moxifloxacin (Table 2).Discussion
An epidemic strain of C. difficile has been associated with outbreaks of C. difficile–associated disease in eight health care facilities since 2001. This strain is the same as the strain responsible for recent outbreaks outside the United States.26,27 It is classified by REA typing as BI and by PFGE as NAP1, and is distinct from the J strain (REA type J7/9) that was responsible for outbreaks during the period from 1989 through 1992.28 Eighteen related isolates of the BI REA group, obtained from 14 known U.S. cases of C. difficile–associated disease that occurred between 1984 and 1993, were found in a database of more than 6000 isolates (representing more than 100 REA groups). According to PFGE dendrographic analysis, the majority of BI/NAP1 strain isolates (including historic BI isolates) were more than 90 percent related, and all were more than 80 percent related. Although current BI/NAP1 isolates shared with historic BI isolates the putative virulence factors of binary toxin and an 18-bp deletion in tcdC, the current isolates were more likely to be resistant to fluoroquinolones. Therefore, the increasing use of fluoroquinolones in U.S. health care facilities may have provided a selective advantage for this epidemic strain and promoted its widespread emergence.
The most compelling evidence of an increase in the severity of C. difficile–associated disease in the United States is found in the reports from Pennsylvania Facility A, where an increase in both the number of cases and the severity of the disease was noted in 2000 and 2001.12-14 In addition, there was evidence of higher white-cell counts and more severe disease in patients infected with BI/NAP1 strains than in those infected with non-BI/NAP1 strains at the Illinois facility in our study.29 Another report from a Connecticut hospital indicates an increase in the number of cases of severe disease necessitating colectomy during a recent outbreak associated with the BI/NAP1 strain.30 However, reports of other outbreaks, such as the outbreak in the Georgia long-term care facility included in our study, do not suggest increased disease severity.16 Even in the case of Pennsylvania Facility A, investigators were unable to find a significant association between the occurrence of severe C. difficile–associated disease and infection with the outbreak strain (P=0.23).14 Therefore, other factors, such as underlying host susceptibility, prevailing practices of the use of antimicrobial agents or approaches to the treatment of C. difficile–associated disease, may have an important role in the causation of severe disease.
The importance of binary toxin CDT as a virulence factor in C. difficile has not been established; however, a similar toxin, iota toxin, is responsible for virulence in C. perfringens.22 In previous reports, binary toxin CDT was found in only about 6 percent of C. difficile isolates20,21,31; therefore, our finding that the prevalence of this toxin is much higher in isolates from outbreaks associated with increased morbidity suggests that it could, indeed, affect the severity of C. difficile–associated disease. Previous studies have indicated that C. difficile strains with binary toxin CDT nearly always have polymorphisms in the PaLoc.21 Binary toxin CDT has been associated with several different toxinotype patterns31; in our isolates, it was associated with toxinotype III, which was infrequently found in previous clinical surveys. Pseudomembranous colitis is more frequent among patients infected with C. difficile of toxinotype III than among patients infected with C. difficile of other toxinotypes, suggesting that this toxinotype is associated with increased severity of the disease.19,21
The importance of the 18-bp deletion in tcdC is currently unknown. Although tcdC is a proposed negative regulator of the production of toxins A and B, it is not known whether this 18-bp deletion would render a tcdC product nonfunctional and lead to increased production of toxins A and B.23,24 A recent report, however, indicates that BI/NAP1 isolates in vitro do, indeed, produce toxins A and B in considerably greater quantities and at higher rates than non-BI/NAP1 isolates.27 Nonetheless, additional research on the effects of binary toxin CDT and of tcdC deletions on the severity of C. difficile–associated disease appears warranted.
In addition to geographic variation in disease severity, there is variation in the role of particular fluoroquinolones as risk factors in these outbreaks. The outbreak in the Georgia long-term care facility occurred after a change in the formulary from levofloxacin to a C-8-methoxy fluoroquinolone, gatifloxacin.16 Gatifloxacin was an important risk factor for C. difficile–associated disease among patients, and the outbreak resolved after a formulary switch back to levofloxacin. The authors hypothesized that the higher antianaerobic activity of gatifloxacin than of levofloxacin led to a greater alteration in bowel flora and that this, combined with resistance to fluoroquinolone in the prevailing C. difficile strain, contributed to the outbreak.16
Similarly, in Pennsylvania Facility B, the outbreak started within three months after a switch in the formulary from levofloxacin to a C-8-methoxy fluoroquinolone (moxifloxacin); the preliminary results of a case–control study identify moxifloxacin as a risk factor for C. difficile–associated disease during the outbreak.32 In Pennsylvania Facility A, C. difficile–associated disease was associated with the use of levofloxacin, clindamycin, and ceftriaxone.13 However, a higher proportion of cases of C. difficile–associated disease was associated with levofloxacin (31 percent) than with clindamycin (10 percent) or ceftriaxone (7 percent).
The emergence of a previously uncommon strain of C. difficile that is more resistant and potentially more virulent than other strains indicates a need for inpatient health care facilities in North America to track the incidence of C. difficile–associated disease. Clinical outcomes of patients with C. difficile–associated disease should also be monitored, especially if an increase in rates is noted. If an increase in the proportion of severe cases is noted, special consideration should be given to the need for early diagnosis and treatment. Strict infection-control measures, including contact precautions, should be instituted for all patients with C. difficile–associated disease. In contact precautions, the patient is placed in a room alone or with another patient with C. difficile–associated disease, health care workers wear gloves and gowns when entering the room, and patient-care equipment (such as blood-pressure cuffs and stethoscopes) either is used only for the patient or is cleaned before it is used for another patient.33 Enhanced environmental cleaning with dilute bleach should be used to eliminate C. difficile spores.34 Because alcohol is ineffective in killing C. difficile spores, it is prudent for health care workers to wash their hands with soap and water, rather than with alcohol-based waterless hand sanitizers, when caring for patients with C. difficile–associated disease during an outbreak.35
Finally, an important method of controlling past outbreaks of C. difficile–associated disease has been restriction of the use of antimicrobial agents implicated as risk factors for the disease.36 Whether a large-scale restriction of the use of these antimicrobial agents could slow the geographic spread of the BI/NAP1 strain is not known. Because fluoroquinolones have become a mainstay in the treatment of several common infections, a large-scale restriction of the use of these drugs would be quite difficult. However, if this epidemic strain continues to spread and to contribute to increased morbidity and mortality, it will be important either to reconsider the use of fluoroquinolones or to develop other innovative measures for controlling C. difficile–associated disease.
Presented in part at the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, October 1–3, 2004.
Supported in part by grants from the Department of Veterans Affairs Research Service (to Drs. Johnson and Gerding).
Dr. Owens reports having received research funding from Elan, Bayer, Ortho-McNeil, and Pfizer; Dr. Johnson, research funding from Salix Pharmaceuticals and consulting fees or fees for service on an advisory board from Genzyme, Acambis, ViroPharma, and Salix Pharmaceuticals; and Dr. Gerding, research funding from Presutti Laboratories, ActivBiotics, Oscient Pharmaceuticals, and Optimer Pharmaceuticals and consulting fees or fees for serving on an advisory board from Acambis, Oscient Pharmaceuticals, ViroPharma, Genzyme, Optimer Pharmaceuticals, and Salix Pharmaceuticals. Dr. Gerding holds U.S., Canadian, and European Union patents for the use of nontoxigenic C. difficile to treat and prevent C. difficile infection.
We are indebted to the members of the Clostridium difficile Investigation Team for making isolates available for study or otherwise assisting in the characterization and analysis of isolates: Jemelae Bessette, Priscilla Biller, Adam Cheknis, Robert Gaynes, Carol Genese, Kathleen Gensheimer, David Gilbert, Lee Harrison, Bette Jensen, Susan Kohlhepp, James Martin, Linda McDougal, Michelle Merrigan, Carlene Muto, Gary Noskin, Sandra Reiner, Corey Robertson, Kathleen Roye-Horn, Steve Sears, Farida Siddiqui, Sarah Slaughter, Lisa Tkatch, Marty Topiel, August J. Valenti, Carol Ward, Kim Ware, John Warren, Lois Wiggs, Teresa Zembower, and Walter Zukowski.
Source Information
From the Epidemiology and Laboratory Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta (L.C.M., G.E.K., A.T., S.V.K.); the Departments of Pharmacy and Infectious Diseases, Maine Medical Center, Portland (R.C.O.); the College of Medicine, University of Vermont, Burlington (R.C.O.); and the Infectious Disease Section and Research Service, Department of Medicine, Hines Veterans Affairs Hospital and Loyola University Stritch School of Medicine, Hines, Ill. (S.P.S., S.J., D.N.G.).
Address reprint requests to Dr. McDonald at 1600 Clifton Rd., MS A35, Atlanta, GA 30333, or at cmcdonald1@cdc.gov.
- References
References
1
Bartlett JG . Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-339
Full Text | Web of Science | Medline2
Bartlett JG ,Onderdonk AB ,Cisneros RL ,Kasper DL . Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136:701-705
CrossRef | Web of Science | Medline3
Bartlett JG ,Chang T ,Taylor NS ,Onderdonk AB . Colitis induced by Clostridium difficile. Rev Infect Dis 1979;1:370-378
CrossRef | Medline4
Taylor NS ,Bartlett JG . Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev Infect Dis 1979;1:379-385
CrossRef | Medline5
Taylor NS ,Thorne GM ,Bartlett JG . Comparison of two toxins produced by Clostridium difficile. Infect Immun 1981;34:1036-1043
Web of Science | Medline6
Johal SS ,Hammond J ,Solomon K ,James PD ,Mahida YR . Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673-677
CrossRef | Web of Science | Medline7
Johnson S ,Samore MH ,Farrow KA , et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341:1645-1651
Full Text | Web of Science | Medline8
Rubin MS ,Bodenstein LE ,Kent KC . Severe Clostridium difficile colitis. Dis Colon Rectum 1995;38:350-354
CrossRef | Web of Science | Medline9
Kyne L ,Hamel MB ,Polavaram R ,Kelly CP . Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-353
CrossRef | Web of Science | Medline10
Archibald LK ,Banerjee SN ,Jarvis WR . Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004;189:1585-1589
CrossRef | Web of Science | Medline11
McDonald LC, Banerjee S, Jernigan DB. Increasing incidence of Clostridium difficile-associated disease in U.S. acute care hospitals, 1993-2001. In: Proceedings of 14th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, Philadelphia, April 17-20, 2004. abstract.
12
Dallal RM ,Harbrecht BG ,Boujoukas AJ , et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363-372
CrossRef | Web of Science | Medline13
Muto CA ,Pokrywka M ,Shutt K , et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-280
CrossRef | Web of Science | Medline14
McEllistrem MC ,Carman RJ ,Gerding DN ,Genheimer CW ,Zheng L . A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005;40:265-272
CrossRef | Web of Science | Medline15
Layton BA, McDonald LC, Gerding DN, Liedtke LA, Strausbaugh LJ. Perceived increases in the incidence and severity of Clostridium difficile disease: an emerging threat that continues to unfold. In: Proceedings of 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, Los Angeles, April 9-12, 2005. abstract.
16
Gaynes R ,Rimland D ,Killum E , et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-645
CrossRef | Web of Science | Medline17
Clabots CR ,Johnson S ,Bettin KM , et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 1993;31:1870-1875
Web of Science | Medline18
Klaassen CH ,van Haren HA ,Horrevorts AM . Molecular fingerprinting of Clostridium difficile isolates: pulsed-field gel electrophoresis versus amplified fragment length polymorphism. J Clin Microbiol 2002;40:101-104
CrossRef | Web of Science | Medline19
Rupnik M ,Avesani V ,Janc M ,von Eichel-Streiber C ,Delmee M . A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998;36:2240-2247
Web of Science | Medline20
Stubbs S ,Rupnik M ,Gibert M ,Brazier J ,Duerden B ,Popoff M . Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000;186:307-312
CrossRef | Web of Science | Medline21
Geric B ,Rupnik M ,Gerding DN ,Grabnar M ,Johnson S . Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 2004;53:887-894
CrossRef | Web of Science | Medline22
Gulke I ,Pfeifer G ,Liese J , et al. Characterization of the enzymatic component of the ADP-ribosyltransferase toxin CDTa from Clostridium difficile. Infect Immun 2001;69:6004-6011
CrossRef | Web of Science | Medline23
Spigaglia P ,Mastrantonio P . Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002;40:3470-3475
CrossRef | Web of Science | Medline24
Spigaglia P ,Mastrantonio P . Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol 2004;53:1129-1136
CrossRef | Web of Science | Medline25
National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 6th ed. Approved standard M11-A6. Villanova, Pa.: NCCLS, 2004.
26
Loo VG ,Poirier L ,Miller MA , et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449
Full Text | Web of Science | Medline27
Warny M ,Pepin J ,Fang A , et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-1084
CrossRef | Web of Science | Medline28
Samore M ,Killgore G ,Johnson S , et al. Multicenter typing comparison of sporadic and outbreak Clostridium difficile isolates from geographically diverse hospitals. J Infect Dis 1997;176:1233-1238
CrossRef | Web of Science | Medline29
Patel S, Noskin GA, Warren J, et al. Increased severity of disease among patients infected with a newly recognized and widely disseminated epidemic strain of Clostridium difficile. In: Proceedings of 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, Los Angeles, April 9-12, 2005. abstract.
30
Boyce JM, Havell N, McDonald LC, et al. An outbreak of severe Clostridium difficile-associated disease (CDAD) involving an epidemic strain. In: Proceedings of the 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, Los Angeles, April 9-12, 2005. abstract.
31
Goncalves C ,Decre D ,Barbut F ,Burghoffer B ,Petit JC . Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004;42:1933-1939
CrossRef | Web of Science | Medline32
Biller P, Shank B, Tkatch L, Lind L, McDonald LC. Moxifloxacin use as a risk factor in an outbreak of Clostridium difficile-associated disease. In: Proceedings of the 2005 Annual Conference of the Association for Professionals in Infection Control and Epidemiology, Baltimore, June 19-21, 2005. abstract.
33
Garner JS . Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996;17:53-80[Erratum, Infect Control Hosp Epidemiol 1996;17:214.]
CrossRef | Medline34
Sehulster L ,Chinn RY . Guidelines for environmental infection control in health-care facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003;55:1-4235
Boyce JM ,Pittet D . Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002;23:Suppl:S3-S40
CrossRef | Web of Science | Medline36
Gerding DN ,Johnson S ,Peterson LR ,Mulligan ME ,Silva J Jr . Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-477
CrossRef | Web of Science | Medline
- Citing Articles (439)
Citing Articles
1
Philip Toltzis, Michelle M. Nerandzic, Elie Saade, Mary Ann O’Riordan, Sarah Smathers, Theoklis Zaoutis, Jason Kim, Curtis J. Donskey. (2012) High Proportion of False-Positive Clostridium difficile Enzyme Immunoassays for Toxin A and B in Pediatric Patients. Infection Control and Hospital Epidemiology 33:2, 175-179
CrossRef2
S. Johnson. (2012) Clostridium difficile Toxins and Severe C. difficile Infection. Journal of Infectious Diseases 205:3, 353-354
CrossRef3
C. H. Chilton, J. Freeman, G. S. Crowther, S. L. Todhunter, S. Nicholson, M. H. Wilcox. (2012) Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. Journal of Antimicrobial Chemotherapy
CrossRef4
John P. Flaherty, Michael P. Angarone. 2012. Acute Diarrhea and Vomiting. , 72-83.
CrossRef5
Helen Valentine, Erin K. Daugherity, Bhupinder Singh, Kirk J. Maurer. 2012. The Experimental Use of Syrian Hamsters. , 875-906.
CrossRef6
Courtney R. Murphy, Taliser R. Avery, Erik R. Dubberke, Susan S. Huang. (2012) Frequent Hospital Readmissions for Clostridium difficile Infection and the Impact on Estimates of Hospital-Associated C. difficile Burden. Infection Control and Hospital Epidemiology 33:1, 20-28
CrossRef7
Daniel T. Grima, Glenn F. Webb, Erika M. C. D'Agata. (2012) Mathematical Model of the Impact of a Nonantibiotic Treatment for Clostridium difficile on the Endemic Prevalence of Vancomycin-Resistant Enterococci in a Hospital Setting. Computational and Mathematical Methods in Medicine 2012, 1-8
CrossRef8
Jason W. Lancaster, S. James Matthews. (2012) Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile Infections. Clinical Therapeutics 34:1, 1-13
CrossRef9
Kathleen M. McMullen, Jennie L. Mayfield, Angela Abdul-Hakim, David K. Warren, Erik R. Dubberke. (2012) Assessing colectomies due to Clostridium difficile infection: Increases in the community, but not in the referral center. American Journal of Infection Control
CrossRef10
Katharine A. Germansky, Ciarán P. Kelly. (2012) Clostridium difficile Infection. Hospital Medicine Clinics
CrossRef11
J. H. Boone, M. Goodykoontz, S. J. Rhodes, K. Price, J. Smith, K. N. Gearhart, R. J. Carman, T. M. Kerkering, T. D. Wilkins, D. M. Lyerly. (2011) Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. European Journal of Clinical Microbiology & Infectious Diseases
CrossRef12
M. REIL, M. P. M. HENSGENS, E. J. KUIJPER, T. JAKOBIAK, H. GRUBER, M. KIST, S. BORGMANN. (2011) Seasonality of Clostridium difficile infections in Southern Germany. Epidemiology and Infection1-7
CrossRef13
A. A. Venugopal, S. Johnson. (2011) Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection. Clinical Infectious Diseases
CrossRef14
E.C. Keessen, W. Gaastra, L.J.A. Lipman. (2011) Clostridium difficile infection in humans and animals, differences and similarities. Veterinary Microbiology 153:3-4, 205-217
CrossRef15
K. W. Garey, S. S. Ghantoji, D. N. Shah, M. Habib, V. Arora, Z.-D. Jiang, H. L. DuPont. (2011) A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 66:12, 2850-2855
CrossRef16
Chaitanya Pant, Thomas J. Sferra, Abhishek Deshpande, Anil Minocha. (2011) Clinical approach to severe Clostridium difficile infection: Update for the hospital practitioner. European Journal of Internal Medicine 22:6, 561-568
CrossRef17
Mamun-Ur Rashid, Andrej Weintraub, Carl Erik Nord. (2011) Effect of new antimicrobial agents on the ecological balance of human microflora. Anaerobe
CrossRef18
Glen P. Carter, Julian I. Rood, Dena Lyras. (2011) The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends in Microbiology
CrossRef19
Jacques Pépin, Milagros Gonzales Fuentes, Louis Valiquette. (2011) Risk of secondary cases of Clostridium difficile infection among household contacts of index cases. Journal of Infection
CrossRef20
F. Barbut, A. Monnier, C. Eckert. (2011) Infections à Clostridium difficile : aspects cliniques épidémiologiques et thérapeutiques. Réanimation
CrossRef21
I. T. Balassiano, E. A. Yates, R. M. C. P. Domingues, E. d. O. Ferreira. (2011) Clostridium difficile: a problem of concern in developed countries and still a mystery in Latin America.. Journal of Medical Microbiology
CrossRef22
Sahil Khanna, Darrell S Pardi, Scott L Aronson, Patricia P Kammer, Robert Orenstein, Jennifer L St Sauver, W Scott Harmsen, Alan R Zinsmeister. (2011) The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study. The American Journal of Gastroenterology
CrossRef23
M. Kamboj, P. Khosa, A. Kaltsas, N. E. Babady, C. Son, K. A. Sepkowitz. (2011) Relapse Versus Reinfection: Surveillance of Clostridium difficile Infection. Clinical Infectious Diseases 53:10, 1003-1006
CrossRef24
Anilrudh A. Venugopal, Kathleen Riederer, Shilpa M. Patel, Susanna Szpunar, Houssein Jahamy, Sharon Valenti, Stephen P. Shemes, Riad Khatib, Leonard B. Johnson. (2011) Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting. Scandinavian Journal of Infectious Diseases1-7
CrossRef25
Alvine Adrienne Kamdeu Fansi, Jason Robert Guertin, Jacques LeLorier. (2011) Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. Journal of Medical Economics1-8
CrossRef26
Miquel Sabrià. (2011) Hacia una mayor concienciación de la infección asociada a Clostridium difficile. Medicina Clínica 137:13, 591-593
CrossRef27
A. Goorhuis, S. B. Debast, J. C. Dutilh, C. M. van Kinschot, C. Harmanus, S. C. Cannegieter, E. C. Hagen, E. J. Kuijper. (2011) Type-Specific Risk Factors and Outcome in an Outbreak With 2 Different Clostridium difficile Types Simultaneously in 1 Hospital. Clinical Infectious Diseases 53:9, 860-869
CrossRef28
Dimitri M. Drekonja, William H. Amundson, Douglas D. DeCarolis, Michael A. Kuskowski, Frank A. Lederle, James R. Johnson. (2011) Antimicrobial Use and Risk for Recurrent Clostridium difficile Infection. The American Journal of Medicine 124:11, 1081.e1-1081.e7
CrossRef29
C. W. Knetsch, M. P. M. Hensgens, C. Harmanus, M. W. van der Bijl, P. H. M. Savelkoul, E. J. Kuijper, J. Corver, H. C. van Leeuwen. (2011) Genetic markers for Clostridium difficile lineages linked to hypervirulence. Microbiology 157:11, 3113-3123
CrossRef30
Fred C. Tenover, Ellen Jo Baron, Lance R. Peterson, David H. Persing. (2011) Laboratory Diagnosis of Clostridium difficile Infection. The Journal of Molecular Diagnostics 13:6, 573-582
CrossRef31
M. Reil, M. Erhard, E. J. Kuijper, M. Kist, H. Zaiss, W. Witte, H. Gruber, S. Borgmann. (2011) Recognition of Clostridium difficile PCR-ribotypes 001, 027 and 126/078 using an extended MALDI-TOF MS system. European Journal of Clinical Microbiology & Infectious Diseases 30:11, 1431-1436
CrossRef32
Andrea Lo Vecchio, George M. Zacur. (2011) Clostridium difficile infection. Current Opinion in Gastroenterology1
CrossRef33
Carroll Karen C., Bartlett John G.. (2011) Biology of Clostridium difficile : Implications for Epidemiology and Diagnosis. Annual Review of Microbiology 65:1, 501-521
CrossRef34
O.A. Lungulescu, W. Cao, E. Gatskevich, L. Tlhabano, J.G. Stratidis. (2011) CSI: a severity index for Clostridium difficile infection at the time of admission. Journal of Hospital Infection 79:2, 151-154
CrossRef35
Li Wang, David B. Stewart. (2011) Increasing hospital costs for Clostridium difficile colitis: Type of hospital matters. Surgery 150:4, 727-735
CrossRef36
Udayakumar Navaneethan, Saurabh Mukewar, Preethi GK Venkatesh, Rocio Lopez, Bo Shen. (2011) Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. Journal of Crohn's and Colitis
CrossRef37
Vanessa Stevens, Ghinwa Dumyati, Jack Brown, Edwin Wijngaarden. (2011) Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiology and Drug Safety 20:10, 1035-1042
CrossRef38
F. Barbut, M. Monot, A. Rousseau, S. Cavelot, T. Simon, B. Burghoffer, V. Lalande, J. Tankovic, J.-C. Petit, B. Dupuy, C. Eckert. (2011) Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR. European Journal of Clinical Microbiology & Infectious Diseases 30:10, 1279-1285
CrossRef39
Gregory T. Matsuura, Mark W. Garrison. (2011) Antibiotic Collateral Damage: Resistance and Antibiotic-Associated Diarrhea. Hospital Pharmacy 46:10, 758-768
CrossRef40
Kirk M. Doing, Marilyn S. Hintz. (2011) Prospective evaluation of the Meridian Illumigene™ loop-mediated amplification assay and the Gen Probe ProGastro™ Cd polymerase chain reaction assay for the direct detection of toxigenic Clostridium difficile from fecal samples. Diagnostic Microbiology and Infectious Disease
CrossRef41
Abhishek Deshpande, Chaitanya Pant, Vinay Pasupuleti, David D.K. Rolston, Anil Jain, Narayan Deshpande, Priyaleela Thota, Thomas J. Sferra, Adrian V. Hernandez. (2011) Association between Proton Pump Inhibitor therapy and Clostridium difficile infection in a Meta-Analysis. Clinical Gastroenterology and Hepatology
CrossRef42
Jason Kim, Julia F. Shaklee, Sarah Smathers, Priya Prasad, Lindsey Asti, Joan Zoltanski, Michael Dul, Michelle Nerandzic, Susan E. Coffin, Philip Toltzis, Theoklis Zaoutis. (2011) Risk Factors and Outcomes Associated With Severe Clostridium difficile Infection in Children. The Pediatric Infectious Disease Journal1
CrossRef43
H.-J. Kim, S. H. Jeong, M. Kim, Y. Lee, K. Lee. (2011) Detection of Clostridium difficile Toxin A/B Genes by Multiplex Real-Time PCR for the Diagnosis of C. difficile infection. Journal of Medical Microbiology
CrossRef44
P. Papatheodorou, J. E. Carette, G. W. Bell, C. Schwan, G. Guttenberg, T. R. Brummelkamp, K. Aktories. (2011) Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proceedings of the National Academy of Sciences 108:39, 16422-16427
CrossRef45
Richard L Nelson, Philippa Kelsey, Hayley Leeman, Naomi Meardon, Haymesh Patel, Kim Paul, Richard Rees, Ben Taylor, Elizabeth Wood, Rexanna Malakun, Richard L Nelson. 2011. Antibiotic treatment for Clostridium difficile -associated diarrhea in adults. .
CrossRef46
Shailesh Jain, Ciaren Graham, Robert L. J. Graham, Geoff McMullan, Nigel G. Ternan. (2011) Quantitative Proteomic Analysis of the Heat Stress Response in Clostridium difficile Strain 630. Journal of Proteome Research 10:9, 3880-3890
CrossRef47
H.-J. Epple, M. Zeitz. (2011) Enteritis infectiosa. Der Internist 52:9, 1038-1046
CrossRef48
Jennifer S Hardesty, Paul Juang. (2011) Fidaxomicin: A Macrocyclic Antibiotic for the Treatment of Clostridium difficile Infection. Pharmacotherapy 31:9, 877-886
CrossRef49
L. M. Green, T. Worthington, A. C. Hilton, P. A. Lambert. (2011) Genetic characterization of clinical isolates of Clostridium difficile using an optimized RAPD protocol and PCR ribotyping reveals strain diversity between two tertiary referral Trusts in the West Midlands, UK. Journal of Medical Microbiology 60:9, 1287-1291
CrossRef50
Stephanie R. Black, Kingsley N. Weaver, Roderick C. Jones, Kathleen A. Ritger, Laurica A. Petrella, Susan P. Sambol, Michael Vernon, Stephanie Burton, Sylvia Garcia-Houchins, Stephen G. Weber, Mary Alice Lavin, Dale Gerding, Stuart Johnson, Susan I. Gerber. (2011) Clostridium difficile Outbreak Strain BI Is Highly Endemic in Chicago Area Hospitals. Infection Control and Hospital Epidemiology 32:9, 897-902
CrossRef51
David B. Stewart, Christopher S. Hollenbeak. (2011) Clostridium difficile Colitis: Factors Associated with Outcome and Assessment of Mortality at a National Level. Journal of Gastrointestinal Surgery 15:9, 1548-1555
CrossRef52
V. Arora, S. Kachroo, S.S. Ghantoji, H.L. DuPont, K.W. Garey. (2011) High Horn’s index score predicts poor outcomes in patients with Clostridium difficile infection. Journal of Hospital Infection 79:1, 23-26
CrossRef53
Adam P. Roberts, Peter Mullany. (2011) Tn916-like genetic elements: a diverse group of modular mobile elements conferring antibiotic resistance. FEMS Microbiology Reviews 35:5, 856-871
CrossRef54
S. Augustine, R. A. Bonomo. (2011) Taking stock of infections and antibiotic resistance in the elderly and long-term care facilities: A survey of existingand upcoming challenges. European Journal of Microbiology and Immunology 1:3, 190-197
CrossRef55
Roger B. Harvey, Keri N. Norman, Kathleen Andrews, Michael E. Hume, Charles M. Scanlan, Todd R. Callaway, Robin C. Anderson, David J. Nisbet. (2011) Clostridium difficile in Poultry and Poultry Meat. Foodborne Pathogens and Disease110830094201000
CrossRef56
J. G. Bartlett. (2011) A Call to Arms: The Imperative for Antimicrobial Stewardship. Clinical Infectious Diseases 53:suppl 1, S4-S7
CrossRef57
Melina Kachrimanidou, Nikolaos Malisiovas. (2011) Clostridium difficile Infection: A Comprehensive Review. Critical Reviews in Microbiology 37:3, 178-187
CrossRef58
D. S. Metcalf, J. S. Weese. (2011) Binary toxin locus analysis in Clostridium difficile. Journal of Medical Microbiology 60:8, 1137-1145
CrossRef59
Frédéric Barbut, Gabrielle Jones, Catherine Eckert. (2011) Epidemiology and control of Clostridium difficile infections in healthcare settings. Current Opinion in Infectious Diseases 24:4, 370-376
CrossRef60
S. Tyler Phillips, Kristin Nagaro, Susan P. Sambol, Stuart Johnson, Dale N. Gerding. (2011) Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones. Anaerobe 17:4, 166-169
CrossRef61
D.F. Florescu, C. Mindru, H.E. Chambers, A.C. Kalil. (2011) Clostridium difficile and cytomegalovirus colitis co-infection: search for the hidden ‘bug’. Transplant Infectious Disease 13:4, 411-415
CrossRef62
H. Kato, Y. Arakawa. (2011) Use of the loop-mediated isothermal amplification method for identification of PCR ribotype 027 Clostridium difficile. Journal of Medical Microbiology 60:8, 1126-1130
CrossRef63
C. Eckert, F. Vromman, A. Halkovich, F. Barbut. (2011) Multilocus variable-number tandem repeat analysis: a helpful tool for subtyping French Clostridium difficile PCR ribotype 027 isolates. Journal of Medical Microbiology 60:8, 1088-1094
CrossRef64
H. Pituch, P. Obuch-Woszczatynski, D. Wultanska, G. Nurzynska, C. Harmanus, A. Banaszkiewicz, A. Radzikowski, M. Luczak, A. van Belkum, E. Kuijper. (2011) Characterization and antimicrobial susceptibility of Clostridium difficile strains isolated from adult patients with diarrhoea hospitalized in two university hospitals in Poland, 2004-2006. Journal of Medical Microbiology 60:8, 1200-1205
CrossRef65
Robert J. Carman, Adam L. Stevens, Matthew W. Lyerly, Megan F. Hiltonsmith, Bradley G. Stiles, Tracy D. Wilkins. (2011) Clostridium difficile binary toxin (CDT) and diarrhea. Anaerobe 17:4, 161-165
CrossRef66
S. Janezic, A. Indra, F. Allerberger, M. Rupnik. (2011) Use of different molecular typing methods for the study of heterogeneity within Clostridium difficile toxinotypes V and III. Journal of Medical Microbiology 60:8, 1101-1107
CrossRef67
J. Hemminger, J.-M. Balada-Llasat, M. Raczkowski, M. Buckosh, P. Pancholi. (2011) Two case reports of Clostridium difficile bacteremia, one with the epidemic NAP-1 strain. Infection 39:4, 371-373
CrossRef68
K. Solomon, S. Murray, L. Scott, S. McDermott, D. Drudy, A. Martin, C. O'Donoghue, M. Skally, K. Burns, L. Fenelon, F. Fitzpatrick, L. Kyne, S. Fanning. (2011) An investigation of the subtype diversity of clinical isolates of Irish Clostridium difficile ribotypes 027 and 078 by repetitive-extragenic palindromic PCR. Journal of Medical Microbiology 60:8, 1080-1087
CrossRef69
Johannes J. Zeiser, Jennifer Klodmann, Hans-Peter Braun, Ralf Gerhard, Ingo Just, Andreas Pich. (2011) Effects of Clostridium difficile Toxin A on the proteome of colonocytes studied by differential 2D electrophoresis. Journal of Proteomics
CrossRef70
Zhuolin Han, Kathleen M. McMullen, Anthony J. Russo, Susan M. Copper, David K. Warren, Erik R. Dubberke. (2011) A Clostridium difficile infection “intervention”: Change in toxin assay results in fewer C difficile infection cases without changes in patient outcomes. American Journal of Infection Control
CrossRef71
E. R. Dubberke, A. M. Butler, H. A. Nyazee, K. A. Reske, D. S. Yokoe, J. Mayer, J. E. Mangino, Y. M. Khan, V. J. Fraser, . (2011) The Impact of ICD-9-CM Code Rank Order on the Estimated Prevalence of Clostridium difficile Infections. Clinical Infectious Diseases 53:1, 20-25
CrossRef72
V. Stevens, G. Dumyati, L. S. Fine, S. G. Fisher, E. van Wijngaarden. (2011) Cumulative Antibiotic Exposures Over Time and the Risk of Clostridium difficile Infection. Clinical Infectious Diseases 53:1, 42-48
CrossRef73
Greta L. Krapohl, Laurel R. S. Phillips, Darrell A. Campbell, Samantha Hendren, Mousumi Banerjee, Bonnie Metzger, Arden M. Morris. (2011) Bowel Preparation for Colectomy and Risk of Clostridium difficile Infection. Diseases of the Colon & Rectum 54:7, 810-817
CrossRef74
Thomas J. Sandora, Monica Fung, Kathleen Flaherty, Laura Helsing, Patricia Scanlon, Gail Potter-Bynoe, Courtney A. Gidengil, Grace M. Lee. (2011) Epidemiology and Risk Factors for Clostridium difficile Infection in Children. The Pediatric Infectious Disease Journal 30:7, 580-584
CrossRef75
Kathleen M Mullane, Sherwood Gorbach. (2011) Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Review of Anti-infective Therapy 9:7, 767-777
CrossRef76
S. D. Baines, A. R. Noel, G. S. Huscroft, S. L. Todhunter, R. O'Connor, J. K. Hobbs, J. Freeman, A. M. Lovering, M. H. Wilcox. (2011) Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. Journal of Antimicrobial Chemotherapy 66:7, 1537-1546
CrossRef77
A. M. Kufelnicka, T. J. Kirn. (2011) Effective Utilization of Evolving Methods for the Laboratory Diagnosis of Clostridium difficile Infection. Clinical Infectious Diseases 52:12, 1451-1457
CrossRef78
Amy Pakyz, Norman V Carroll, Spencer E Harpe, Michael Oinonen, Ronald E Polk. (2011) Economic Impact of Clostridium difficile Infection in a Multihospital Cohort of Academic Health Centers. Pharmacotherapy 31:6, 546-551
CrossRef79
Shilpa M. Patel, Evan Stashefsky, Marie-Claire Maroun, Leonard B. Johnson. (2011) The Impact of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in patients with Clostridium difficile infection. Medical Hypotheses 76:6, 813-815
CrossRef80
J. Scaria, T. Janvilisri, S. Fubini, R. D. Gleed, S. P. McDonough, Y.-F. Chang. (2011) Clostridium difficile Transcriptome Analysis Using Pig Ligated Loop Model Reveals Modulation of Pathways Not Modulated In Vitro. Journal of Infectious Diseases 203:11, 1613-1620
CrossRef81
C. Lanzas, E. R. Dubberke, Z. Lu, K. A. Reske, Y. T. Gröhn. (2011) Epidemiological Model for Clostridium difficile Transmission in Healthcare Settings. Infection Control and Hospital Epidemiology 32:6, 553-561
CrossRef82
Matthias A. Oberli, Marie-Lyn Hecht, Pascal Bindschädler, Alexander Adibekian, Thomas Adam, Peter H. Seeberger. (2011) A Possible Oligosaccharide-Conjugate Vaccine Candidate for Clostridium difficile Is Antigenic and Immunogenic. Chemistry & Biology 18:5, 580-588
CrossRef83
S. E. McNamara, N. Abdujamilova, P. Somsel, M. J. Gordoncillo, J. M. DeDecker, P. C. Bartlett. (2011) Carriage of Clostridium difficile and Other Enteric Pathogens Among a 4-H Avocational Cohort. Zoonoses and Public Health 58:3, 192-199
CrossRef84
Simon D. Goldenberg, Gary L. French. (2011) Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. Journal of Infection 62:5, 355-362
CrossRef85
S. M. McBride, A. L. Sonenshein. (2011) The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology 157:5, 1457-1465
CrossRef86
M. P. M. Hensgens, A. Goorhuis, C. M. J. Kinschot, M. J. T. Crobach, C. Harmanus, E. J. Kuijper. (2011) Clostridium difficile infection in an endemic setting in the Netherlands. European Journal of Clinical Microbiology & Infectious Diseases 30:4, 587-593
CrossRef87
Rada Shakov, Raquel S. Salazar, Silvester K. Kagunye, Walid J. Baddoura, Vincent A. DeBari. (2011) Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. American Journal of Infection Control 39:3, 194-198
CrossRef88
Shigeki Fujitani, W. Lance George, Margie A. Morgan, Stephen Nichols, A. Rekha Murthy. (2011) Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections. American Journal of Infection Control 39:3, 188-193
CrossRef89
Ashwin N. Ananthakrishnan, Emily L. McGinley, Kia Saeian, David G. Binion. (2011) Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 17:4, 976-983
CrossRef90
Anilrudh A. Venugopal, Dale N. Gerding, Stuart Johnson. (2011) Clostridium difficile infection rates and spectrum of disease among peripartum women at one hospital from 2003 to 2007 with molecular typing analysis of recovered Clostridium difficile isolates. American Journal of Infection Control 39:3, 206-211
CrossRef91
Courtney Hebert, Stephen G. Weber. (2011) Common Approaches to the Control of Multidrug-resistant Organisms Other Than Methicillin-resistant Staphylococcus aureus (MRSA). Infectious Disease Clinics of North America 25:1, 181-200
CrossRef92
Shigeki Fujitani, W. Lance George, A. Rekha Murthy. (2011) Comparison of Clinical Severity Score Indices for Clostridium difficile Infection. Infection Control and Hospital Epidemiology 32:3, 220-228
CrossRef93
Julia Shaklee, Danielle M. Zerr, Alexis Elward, Jason Newland, Kateri Leckerman, Lindsey Asti, Rebecca Guth, Julie Bass, Rangaraj Selvarangan, Susan Coffin, Theoklis Zaoutis. (2011) Improving Surveillance for Pediatric Clostridium difficile Infection. The Pediatric Infectious Disease Journal 30:3, e38-e40
CrossRef94
A. Studemeister. (2011) Lack of Health Insurance Coverage for Oral Vancomycin: It's Time to Tackle the Elephant in the Room. Clinical Infectious Diseases 52:5, 691-692
CrossRef95
Susanna Naggie, Becky A. Miller, Kimberly B. Zuzak, Brian W. Pence, Ashley J. Mayo, Bradly P. Nicholson, Preeta K. Kutty, L. Clifford McDonald, Christopher W. Woods. (2011) A Case-control Study of Community-associated Clostridium difficile Infection: No Role for Proton Pump Inhibitors. The American Journal of Medicine 124:3, 276.e1-276.e7
CrossRef96
Brian G. Harbrecht, Glen A. Franklin, Robert M. Shirley, Jason W. Smith, Frank B. Miller, J. David Richardson. (2011) Statewide Experience with Clostridium difficile Colitis in Academic and Nonacademic Medical Centers *. Surgical Infections110306225234014
CrossRef97
David C. Kaslow, John W. Shiver. (2011) Clostridium difficile and Methicillin-Resistant Staphylococcus aureus: Emerging Concepts in Vaccine Development. Annual Review of Medicine 62:1, 201-215
CrossRef98
B. A. Lopman, A. J. Hall, A. T. Curns, U. D. Parashar. (2011) Increasing Rates of Gastroenteritis Hospital Discharges in US Adults and the Contribution of Norovirus, 1996-2007. Clinical Infectious Diseases 52:4, 466-474
CrossRef99
Louie, Thomas J., Miller, Mark A., Mullane, Kathleen M., Weiss, Karl, Lentnek, Arnold, Golan, Yoav, Gorbach, Sherwood, Sears, Pamela, Shue, Youe-Kong, . (2011) Fidaxomicin versus Vancomycin for Clostridium difficile Infection. New England Journal of Medicine 364:5, 422-431
Full Text100
T. Pasanen, S. M. Kotila, J. Horsma, A. Virolainen, J. Jalava, S. Ibrahem, J. Antikainen, S. Mero, E. Tarkka, M. Vaara, P. Tissari. (2011) Comparison of repetitive extragenic palindromic sequence-based PCR with PCR ribotyping and pulsed-field gel electrophoresis in studying the clonality of Clostridium difficile. Clinical Microbiology and Infection 17:2, 166-175
CrossRef101
Ellie JC Goldstein. (2011) Beyond the target pathogen: ecological effects of the hospital formulary. Current Opinion in Infectious Diseases 24:Suppl 1, S21-S31
CrossRef102
E. R. Dubberke, D. B. Haslam, C. Lanzas, L. D. Bobo, C.-A. D. Burnham, Y. T. Gröhn, P. I. Tarr. (2011) The Ecology and Pathobiology of Clostridium difficile Infections: An Interdisciplinary Challenge. Zoonoses and Public Health 58:1, 4-20
CrossRef103
John R. Wingard, Jack Hsu, John W. Hiemenz. (2011) Hematopoietic Stem Cell Transplantation: An Overview of Infection Risks and Epidemiology. Hematology/Oncology Clinics of North America 25:1, 101-116
CrossRef104
Laurent Bouillaut, Shonna M. McBride, Joseph A. Sorg. 2011. Genetic Manipulation of Clostridium difficile. .
CrossRef105
Kelly Lesperance, Marlin Wayne Causey, Michael Spencer, Scott Russell Steele. (2011) The morbidity of Clostridium difficile infection after elective colonic resection—results from a national population database. The American Journal of Surgery 201:2, 141-148
CrossRef106
Revital Kariv, Udayakumar Navaneethan, Preethi G.K. Venkatesh, Rocio Lopez, Bo Shen. (2011) Impact of Clostridium difficile infection in patients with ulcerative colitis. Journal of Crohn's and Colitis 5:1, 34-40
CrossRef107
David Calfee. (2011) Crisis in Hospital-Acquired, Health Care-Associated Infections. Annual Review of Medicine 63:1, 110301100719093
CrossRef108
Benjamin Maurer, Ulf Mathias, Panagiotis Papatheodorou, Suhaib Shekfeh, Joachim Orth, Thomas Jank, Carsten Schwan, Wolfgang Sippl, Klaus Aktories, Manfred Jung. (2011) From cosubstrate similarity to inhibitor diversity—inhibitors of ADP-ribosyltransferases from kinase inhibitor screening. Molecular BioSystems 7:3, 799
CrossRef109
Teena Chopra, Pranatharthi Chandrasekar, Hossein Salimnia, Lance K. Heilbrun, Daryn Smith, George J. Alangaden. (2011) Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clinical Transplantation 25:1, E82-E87
CrossRef110
Daniel M. Autenrieth, Daniel C. Baumgart. (2011) Toxic megacolon. Inflammatory Bowel Diseasesn/a-n/a
CrossRef111
M. A. Slavin, S. Lingaratnam, L. Mileshkin, D. L. Booth, M. J. Cain, D. S. Ritchie, A. Wei, K. A. Thursky. (2011) Use of antibacterial prophylaxis for patients with neutropenia. Internal Medicine Journal 41:1b, 102-109
CrossRef112
Preetika Sinh, Terrence A. Barrett, Laura Yun. (2011) Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterology Research and Practice 2011, 1-11
CrossRef113
Caoilfhionn OʼDonoghue, Lorraine Kyne. (2011) Update on Clostridium difficile infection. Current Opinion in Gastroenterology 27:1, 38-47
CrossRef114
Jennifer A. Unger, Estella Whimbey, Michael G. Gravett, David A. Eschenbach. (2011) The Emergence of Clostridium difficile Infection among Peripartum Women: A Case-Control Study of a C. difficile Outbreak on an Obstetrical Service. Infectious Diseases in Obstetrics & Gynecology 2011, 1-8
CrossRef115
Martijn P Bauer, Daan W Notermans, Birgit HB van Benthem, Jon S Brazier, Mark H Wilcox, Maja Rupnik, Dominique L Monnet, Jaap T van Dissel, Ed J Kuijper. (2011) Clostridium difficile infection in Europe: a hospital-based survey. The Lancet 377:9759, 63-73
CrossRef116
Cirle A Warren, Richard L Guerrant. (2011) Pathogenic C difficile is here (and everywhere) to stay. The Lancet 377:9759, 8-9
CrossRef117
David T. Rubin, Sunana Sohi, Matthew Glathar, Tojo Thomas, Nicole Yadron, Bonnie L. Surma. (2011) Rifaximin Is Effective for the Treatment of Clostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study. Gastroenterology Research and Practice 2011, 1-5
CrossRef118
Ashwin N. Ananthakrishnan. (2011) Clostridium difficile infection: epidemiology, risk factors and management. Nature Reviews Gastroenterology & Hepatology 8:1, 17-26
CrossRef119
Heejung Kim, Yangsoon Lee, Hee-Won Moon, Chae Seung Lim, Kyungwon Lee, Yunsop Chong. (2011) Emergence of Clostridium difficile Ribotype 027 in Korea. The Korean Journal of Laboratory Medicine 31:3, 191
CrossRef120
Judith R. Kelsen, Jason Kim, Dan Latta, Sarah Smathers, Karin L. McGowan, Theodore Zaoutis, Petar Mamula, Robert N. Baldassano. (2011) Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflammatory Bowel Diseases 17:1, 50-55
CrossRef121
Marwan S. Abougergi, John H. Kwon. (2011) Intravenous Immunoglobulin for the Treatment of Clostridium difficile Infection: A Review. Digestive Diseases and Sciences 56:1, 19-26
CrossRef122
Jennifer L Kuntz, Elizabeth A Chrischilles, Jane F Pendergast, Loreen A Herwaldt, Philip M Polgreen. (2011) Incidence of and risk factors for community-associated Clostridium difficile infection: A nested case-control study. BMC Infectious Diseases 11:1, 194
CrossRef123
Ping Zhang, Nahid Razi, Luiz Eugenio, Messele Fentabil, Elena N. Kitova, John S. Klassen, David R. Bundle, Kenneth K.-S. Ng, Chang-Chun Ling. (2011) Unexpected structure of a C. difficile toxin A ligand necessitates an annotation correction in a popular screening library. Chemical Communications 47:45, 12397
CrossRef124
Genevieve McKew, Kate Clezy. (2011) Clinical features, management and infection control of Clostridium difficile infection in an Australian tertiary hospital: a prospective observational study. Healthcare Infection 16:4, 140
CrossRef125
John G. Bartlett. (2010) Clostridium difficile: progress and challenges. Annals of the New York Academy of Sciences 1213:1, 62-69
CrossRef126
C. Ilchmann, N. H. Zaiß, A. Speicher, M. Christner, G. Ackermann, H. Rohde. (2010) Comparison of resistance against erythromycin and moxifloxacin, presence of binary toxin gene and PCR ribotypes in Clostridium difficile isolates from 1990 and 2008. European Journal of Clinical Microbiology & Infectious Diseases 29:12, 1571-1573
CrossRef127
J. Cooke, K. Alexander, E. Charani, K. Hand, T. Hills, P. Howard, C. Jamieson, W. Lawson, J. Richardson, P. Wade. (2010) Antimicrobial stewardship: an evidence-based, antimicrobial self-assessment toolkit (ASAT) for acute hospitals. Journal of Antimicrobial Chemotherapy 65:12, 2669-2673
CrossRef128
Stefano Donadio, Sonia Maffioli, Paolo Monciardini, Margherita Sosio, Daniela Jabes. (2010) Sources of novel antibiotics—aside the common roads. Applied Microbiology and Biotechnology 88:6, 1261-1267
CrossRef129
J Hsu, C Abad, M Dinh, Nasia Safdar. (2010) Prevention of Endemic Healthcare-Associated Clostridium difficile Infection: Reviewing the Evidence. The American Journal of Gastroenterology 105:11, 2327-2339
CrossRef130
Bahman Saatian, Chandralekha Banerjee, Karen C. Carroll, Traci L. Ross, Farin Kamangar. (2010) Characterization of Clostridium difficile Infection and Analysis of Recovered Isolates in a Community Hospital Population in Baltimore, Maryland. Infectious Diseases in Clinical Practice 18:6, 383-388
CrossRef131
R.F. de Boer, J.J. Wijma, T. Schuurman, J. Moedt, B.G. Dijk-Alberts, A. Ott, A.M.D. Kooistra-Smid, Y.T.H.P. van Duynhoven. (2010) Evaluation of a rapid molecular screening approach for the detection of toxigenic Clostridium difficile in general and subsequent identification of the tcdC Δ117 mutation in human stools. Journal of Microbiological Methods 83:1, 59-65
CrossRef132
Ashwin N Ananthakrishnan, David G Binion. (2010) Impact of Clostridium difficile on inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 4:5, 589-600
CrossRef133
Teena Chopra, George J Alangaden, Pranatharthi Chandrasekar. (2010) Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Review of Anti-infective Therapy 8:10, 1113-1119
CrossRef134
Yasuhito Iwashima, Atsushi Nakamura, Haru Kato, Hideaki Kato, Yukio Wakimoto, Naoki Wakiyama, Chiharu Kaji, Ryuzo Ueda. (2010) A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. Journal of Infection and Chemotherapy 16:5, 329-333
CrossRef135
Angira Patel, Jeffrey J. Gossett, Tara Benton, Erin Rowell, Hyde Russell, Elaine Cham, Elfriede Pahl. (2010) Fulminant Clostridium difficile toxic megacolon in a pediatric heart transplant recipient. Pediatric Transplantationno-no
CrossRef136
Alan C. Moss, John Thomas LaMont. 2010. Clostridium difficile Infection and Pseudomembranous Colitis. , 361-366.
CrossRef137
Lynne V McFarland, Christina M Surawicz. 2010. Clostridium Difficile Associated Disease: Diagnosis and Treatment. , 335-354.
CrossRef138
Nicole Knight, Taylor Strait, Nicholas Anthony, Roger Lovell, H. James Norton, Robert Sautter, Martin Scobey. (2010) Clostridium difficile colitis: A retrospective study of incidence and severity before and after institution of an alcohol-based hand rub policy. American Journal of Infection Control 38:7, 523-528
CrossRef139
Latisha Heinlen, Jimmy D. Ballard. (2010) Clostridium difficile Infection. The American Journal of the Medical Sciences 340:3, 247-252
CrossRef140
Alan R. Salkind. (2010) Clostridium difficile: An Update for the Primary Care Clinician. Southern Medical Journal 103:9, 896-902
CrossRef141
Jesse T Jacob, Robert P Gaynes. (2010) Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship. Expert Review of Anti-infective Therapy 8:8, 893-902
CrossRef142
J. Price, E. Cheek, S. Lippett, M. Cubbon, D. N. Gerding, S. P. Sambol, D. M. Citron, M. Llewelyn. (2010) Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. Clinical Microbiology and Infection 16:8, 1297-1302
CrossRef143
Sahil Khanna, Darrell S Pardi. (2010) The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Review of Gastroenterology & Hepatology 4:4, 409-416
CrossRef144
Andrew E. Simor. (2010) Diagnosis, Management, and Prevention of Clostridium difficile Infection in Long-Term Care Facilities: A Review. Journal of the American Geriatrics Society 58:8, 1556-1564
CrossRef145
Jeffrey Ng, Simon A. Hirota, Olaf Gross, Yan Li, Annegret Ulke–Lemee, Mireille S. Potentier, L. Patrick Schenck, Akosua Vilaysane, Mark E. Seamone, Hanping Feng, Glen D. Armstrong, Jurg Tschopp, Justin A. MacDonald, Daniel A. Muruve, Paul L. Beck. (2010) Clostridium difficile Toxin–Induced Inflammation and Intestinal Injury Are Mediated by the Inflammasome. Gastroenterology 139:2, 542-552.e3
CrossRef146
T. Norén, I. Alriksson, T. Åkerlund, L. G. Burman, M. Unemo. (2010) In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clinical Microbiology and Infection 16:8, 1104-1110
CrossRef147
S. Naggie, J. Frederick, B. C. Pien, B. A. Miller, D. T. Provenzale, K. C. Goldberg, C. W. Woods. (2010) Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA. Infection 38:4, 297-300
CrossRef148
Linda D. Bobo, Erik R. Dubberke. (2010) Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Critical Care Medicine 38, S324-S334
CrossRef149
Chintan Modi, Joseph R. DePasquale, Nhat Q. Nguyen, Judith E. Malinowski, George Perez. (2010) Does the handling time of unrefrigerated human fecal specimens impact the detection of Clostridium difficile toxins in a hospital setting?. Indian Journal of Gastroenterology 29:4, 157-161
CrossRef150
Parag Butala, Celia M. Divino. (2010) Surgical aspects of fulminant Clostridium difficile Colitis. The American Journal of Surgery 200:1, 131-135
CrossRef151
Andrea D. Olivas, Konstantin Umanskiy, Brian Zuckerbraun, John C. Alverdy. (2010) Avoiding Colectomy during Surgical Management of Fulminant Clostridium difficile Colitis. Surgical Infections 11:3, 299-305
CrossRef152
J. Ryan, C. Murphy, C. Twomey, R. Paul Ross, M. C. Rea, J. MacSharry, B. Sheil, F. Shanahan. (2010) Asymptomatic carriage of Clostridium difficile in an Irish continuing care institution for the elderly: prevalence and characteristics. Irish Journal of Medical Science 179:2, 245-250
CrossRef153
John R. Wingard, Jack Hsu, John W. Hiemenz. (2010) Hematopoietic Stem Cell Transplantation: An Overview of Infection Risks and Epidemiology. Infectious Disease Clinics of North America 24:2, 257-272
CrossRef154
B. Faris, A. Blackmore, N. Haboubi. (2010) Review of medical and surgical management of Clostridium difficile infection. Techniques in Coloproctology 14:2, 97-105
CrossRef155
James Gasperino, Maya Garala, Hillel W. Cohen, Vladimir Kvetan, Brian Currie. (2010) Investigation of critical care unit utilization and mortality in patients infected with Clostridium difficile. Journal of Critical Care 25:2, 282-286
CrossRef156
Michael B. Rothberg, Penelope S. Pekow, Maureen Lahti, Oren Brody, Daniel J. Skiest, Peter K. Lindenauer. (2010) Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Journal of Hospital Medicine 5:5, 261-267
CrossRef157
H. Kato, H. Kato, Y. Ito, T. Akahane, S. Izumida, T. Yokoyama, C. Kaji, Y. Arakawa. (2010) Typing of Clostridium difficile isolates endemic in Japan by sequencing of slpA and its application to direct typing. Journal of Medical Microbiology 59:5, 556-562
CrossRef158
B. Salzberger. (2010) Clostridium-difficile-Kolitis. Intensivmedizin und Notfallmedizin 47:4, 272-275
CrossRef159
Naomi G Diggs, Christina M Surawicz. (2010) Clostridium difficile infection: still principally a disease of the elderly. Therapy 7:3, 295-301
CrossRef160
M. He, M. Sebaihia, T. D. Lawley, R. A. Stabler, L. F. Dawson, M. J. Martin, K. E. Holt, H. M. B. Seth-Smith, M. A. Quail, R. Rance, K. Brooks, C. Churcher, D. Harris, S. D. Bentley, C. Burrows, L. Clark, C. Corton, V. Murray, G. Rose, S. Thurston, A. van Tonder, D. Walker, B. W. Wren, G. Dougan, J. Parkhill. (2010) Evolutionary dynamics of Clostridium difficile over short and long time scales. Proceedings of the National Academy of Sciences 107:16, 7527-7532
CrossRef161
Rosemarie Metzger, Brian R. Swenson, Hugo Bonatti, Traci L. Hedrick, Tjasa Hranjec, Kimberley A. Popovsky, Timothy L. Pruett, Robert G. Sawyer. (2010) Identification of Risk Factors for the Development of Clostridium difficile-Associated Diarrhea Following Treatment of Polymicrobial Surgical Infections. Annals of Surgery 251:4, 722-727
CrossRef162
S.S. Ghantoji, K. Sail, D.R. Lairson, H.L. DuPont, K.W. Garey. (2010) Economic healthcare costs of Clostridium difficile infection: a systematic review. Journal of Hospital Infection 74:4, 309-318
CrossRef163
S. K. Taori, V. Hall, I. R. Poxton. (2010) Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. Journal of Medical Microbiology 59:3, 338-344
CrossRef164
Scott Curry. (2010) Clostridium difficile. Clinics in Laboratory Medicine 30:1, 329-342
CrossRef165
A. Kola. (2010) Clostridium-difficile-Infektionen. Der Internist 51:2, 154-160
CrossRef166
Kirk M. Doing, Marilyn S. Hintz, Calvin Keefe, Sarah Horne, Shelby LeVasseur, Martha L. Kulikowski. (2010) Reevaluation of the Premier Clostridium difficile toxin A and B immunoassay with comparison to glutamate dehydrogenase common antigen testing evaluating Bartels cytotoxin and Prodesse ProGastro™ Cd polymerase chain reaction as confirmatory procedures. Diagnostic Microbiology and Infectious Disease 66:2, 129-134
CrossRef167
Yury Belyi, Klaus Aktories. (2010) Bacterial toxin and effector glycosyltransferases. Biochimica et Biophysica Acta (BBA) - General Subjects 1800:2, 134-143
CrossRef168
Lowy, Israel, Molrine, Deborah C., Leav, Brett A., Blair, Barbra M., Baxter, Roger, Gerding, Dale N., Nichol, Geoffrey, Thomas, William D. Jr., Leney, Mark, Sloan, Susan, Hay, Catherine A., Ambrosino, Donna M., . (2010) Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. New England Journal of Medicine 362:3, 197-205
Full Text169
Marwan S. Abougergi, Apoorv Broor, Wei Cui, Bernard G. Jaar. (2010) Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: An observational study and review of the literature. Journal of Hospital Medicine 5:1, E1-E9
CrossRef170
Udayakumar Navaneethan, Bo Shen. (2010) Secondary Pouchitis: Those With Identifiable Etiopathogenetic or Triggering Factors. The American Journal of Gastroenterology 105:1, 51-64
CrossRef171
A. Candiotto, I. Pascoli, A. Gritti, E. Busato, G. Dal Pozzo. (2010) Toxic megacolon complicating a Clostridium difficile infection in a pregnant woman. Journal of Medical Microbiology 59:1, 124-126
CrossRef172
Guadalupe Garcia-Tsao, Christina M Surawicz. (2010) Editorial: Clostridium difficile Infection: Yet Another Predictor of Poor Outcome in Cirrhosis. The American Journal of Gastroenterology 105:1, 114-116
CrossRef173
Heejung Kim, Seok Hoon Jeong, Kyoung Ho Roh, Seong Geun Hong, Jong Wan Kim, Myung-Geun Shin, Mi-Na Kim, Hee Bong Shin, Young Uh, Hyukmin Lee, Kyungwon Lee. (2010) Investigation of Toxin Gene Diversity, Molecular Epidemiology, and Antimicrobial Resistance of Clostridium difficile Isolated from 12 Hospitals in South Korea. The Korean Journal of Laboratory Medicine 30:5, 491
CrossRef174
Ashwin N. Ananthakrishnan, Mazen Issa, David G. Binion. (2010) Clostridium Difficile and Inflammatory Bowel Disease. Medical Clinics of North America 94:1, 135-153
CrossRef175
Ping Zhang, Kenneth Ng, Chang-Chun Ling. (2010) Total synthesis of LeA-LacNAc pentasaccharide as a ligand for Clostridium difficile toxin A. Organic & Biomolecular Chemistry 8:1, 128
CrossRef176
Frits R. Mooi. (2010) Bordetella pertussis and vaccination: The persistence of a genetically monomorphic pathogen. Infection, Genetics and Evolution 10:1, 36-49
CrossRef177
Hyunjoo Pai. (2010) Current epidemiology and treatment of Clostridium difficile infection. Infection and Chemotherapy 42:6, 362
CrossRef178
Brett A. Leav, Barbra Blair, Mark Leney, Michael Knauber, Courtney Reilly, Israel Lowy, Dale N. Gerding, Ciarán P. Kelly, Kia Katchar, Roger Baxter, Donna Ambrosino, Deborah Molrine. (2010) Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:4, 965-969
CrossRef179
Brandon P. Verdoorn, Robert Orenstein, Jon E. Rosenblatt, Lynne M. Sloan, Cathy D. Schleck, William S. Harmsen, Lisa M. Nyre, Robin Patel. (2010) High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity. Diagnostic Microbiology and Infectious Disease 66:1, 24-28
CrossRef180
Jill M. Watanabe, Christina M. Surawicz. 2010. Colitis. , 349-354.
CrossRef181
Natasha Bagdasarian, Curtis D Collins, Preeti N Malani. (2009) Treatment of Clostridium difficile infection in older adults. Aging Health 5:6, 753-761
CrossRef182
Martijn P Bauer, Jaap T van Dissel, Ed J Kuijper. (2009) Clostridium difficile: controversies and approaches to management. Current Opinion in Infectious Diseases 22:6, 517-524
CrossRef183
Lina M. Nasereddin, Fares G. Bakri, Asem A. Shehabi. (2009) Clostridium difficile infections among Jordanian adult hospitalized patients. American Journal of Infection Control 37:10, 864-866
CrossRef184
Stephen Weber, Emily Mawdsley, Donald Kaye. (2009) Antibacterial Agents in the Elderly. Infectious Disease Clinics of North America 23:4, 881-898
CrossRef185
Fatemeh Rafii, Miseon Park, Gonçalo Gamboa da Costa, Luisa Camacho. (2009) Comparison of the metabolic activities of four wild-type Clostridium perfringens strains with their gatifloxacin-selected resistant mutants. Archives of Microbiology 191:12, 895-902
CrossRef186
Ashwin N. Ananthakrishnan, Mazen Issa, David G. Binion. (2009) Clostridium Difficile and Inflammatory Bowel Disease. Gastroenterology Clinics of North America 38:4, 711-728
CrossRef187
Miguel Salazar, Lyudmila Baskin, Kevin W. Garey, Herbert L. DuPont. (2009) Clostridium difficile-related death rates in Texas 1999–2005. Journal of Infection 59:5, 303-307
CrossRef188
Christine S. Ho, Julu Bhatnagar, Adam L. Cohen, Jill K. Hacker, Suzanne B. Zane, Sarah Reagan, Marc Fischer, Wun-Ju Shieh, Jeannette Guarner, Shabbir Ahmad, Sherif R. Zaki, L. Clifford McDonald. (2009) Undiagnosed cases of fatal Clostridium-associated toxic shock in Californian women of childbearing age. American Journal of Obstetrics and Gynecology 201:5, 459.e1-459.e7
CrossRef189
M. Raffat Jaber, Joseph H. Ruan, Wesley L. Fung, Mark E. Reeves. (2009) Are vasopressor use and mechanical ventilation the only predictors of worse outcome for fulminant Clostridium difficile infection?. The American Journal of Surgery 198:4, 581-582
CrossRef190
Miguel Salazar, Kevin W. Garey, Zhi-Dong Jiang, Thanh Dao-Tran, Herbert DuPont. (2009) Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharmacy World & Science 31:5, 565-571
CrossRef191
Udayakumar Navaneethan, Bo Shen. (2009) Laboratory Tests for Patients With Ileal Pouch–Anal Anastomosis: Clinical Utility in Predicting, Diagnosing, and Monitoring Pouch Disorders. The American Journal of Gastroenterology 104:10, 2606-2615
CrossRef192
Karin I. Hjalmarson, Sherwood L. Gorbach. 2009. Clostridium difficile Infection in Critical Care. , 271-287.
CrossRef193
S.W. Pawlowski, L. Archbald-Pannone, R.J. Carman, C. Alcantara-Warren, D. Lyerly, C.W. Genheimer, D.N. Gerding, R.L. Guerrant. (2009) Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile. Journal of Hospital Infection 73:2, 185-187
CrossRef194
Newton G. Osborne, Balwant Ahluwalia. (2009) Pseudomembranous Colitis. Journal of Gynecologic Surgery 25:3, 129-131
CrossRef195
Robert C. Owens. (2009) Antimicrobial Stewardship: Application in the Intensive Care Unit. Infectious Disease Clinics of North America 23:3, 683-702
CrossRef196
David J. Riddle, Erik R. Dubberke. (2009) Clostridium difficile Infection in the Intensive Care Unit. Infectious Disease Clinics of North America 23:3, 727-743
CrossRef197
Kenneth V. I. Rolston. (2009) New antimicrobial agents for the treatment of bacterial infections in cancer patients. Hematological Oncology 27:3, 107-114
CrossRef198
O. M. Williams, R. C. Spencer. (2009) The management of Clostridium difficile infection. British Medical Bulletin 91:1, 87-110
CrossRef199
Heikki Lukkarinen, Erkki Eerola, Aino Ruohola, Raija Vainionpää, Jari Jalava, Saara Kotila, Olli Ruuskanen. (2009) CLOSTRIDIUM DIFFICILE RIBOTYPE 027–ASSOCIATED DISEASE IN CHILDREN WITH NOROVIRUS INFECTION. The Pediatric Infectious Disease Journal 28:9, 847-848
CrossRef200
G. Terhes, E. Urb
n, M. Konkoly-Thege,
CrossRef201
Neil Woodford, David M. Livermore. (2009) Infections caused by Gram-positive bacteria: a review of the global challenge. Journal of Infection 59, S4-S16
CrossRef202
Y. Yadav, K.W. Garey, T.K. Dao-Tran, V. Kaila, K.Y.E. Gbito, H.L. DuPont. (2009) Automated system to identify Clostridium difficile infection among hospitalised patients. Journal of Hospital Infection 72:4, 337-341
CrossRef203
JENNI ANTIKAINEN, TANJA PASANEN, SOINTU MERO, EVELIINA TARKKA, JUHA KIRVESKARI, SAARA KOTILA, SILJA MENTULA, EIJA KÖNÖNEN, ANNI-RIITTA VIROLAINEN-JULKUNEN, MARTTI VAARA, PÄIVI TISSARI. (2009) Detection of virulence genes of Clostridium difficile by multiplex PCR. APMIS 117:8, 607-613
CrossRef204
Cassandra D. Salgado, Patrick D. Mauldin, Pamela J. Fogle, John A. Bosso. (2009) Analysis of an outbreak of Clostridium difficile infection controlled with enhanced infection control measures. American Journal of Infection Control 37:6, 458-464
CrossRef205
Robin B. McFee. (2009) Nosocomial or Hospital-acquired Infections: An Overview. Disease-a-Month 55:7, 422-438
CrossRef206
K. Bloedt, M. Riecker, S. Poppert, N. Wellinghausen. (2009) Evaluation of new selective culture media and a rapid fluorescence in situ hybridization assay for identification of Clostridium difficile from stool samples. Journal of Medical Microbiology 58:7, 874-877
CrossRef207
Maja Rupnik, Mark H. Wilcox, Dale N. Gerding. (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nature Reviews Microbiology 7:7, 526-536
CrossRef208
Robin B. McFee, George G. Abdelsayed. (2009) Clostridium difficile. Disease-a-Month 55:7, 439-470
CrossRef209
John C. Marshall, Konrad Reinhart. (2009) Biomarkers of sepsis. Critical Care Medicine 37:7, 2290-2298
CrossRef210
Robin B. McFee. (2009) Introduction. Disease-a-Month 55:7, 419-421
CrossRef211
Sergio Alvarez-Perez, Jose L. Blanco, Emilio Bouza, Patricia Alba, Xavier Gibert, Jaime Maldonado, Marta E. Garcia. (2009) Prevalence of Clostridium difficile in diarrhoeic and non-diarrhoeic piglets. Veterinary Microbiology 137:3-4, 302-305
CrossRef212
Hideaki Kato, Haru Kato, Makoto Nakamura, Yasuhito Iwashima, Atsushi Nakamura, Ryuzo Ueda. (2009) Rapid analysis of Clostridium difficile strains recovered from hospitalized patients by using the slpA sequence typing system. Journal of Infection and Chemotherapy 15:3, 199-202
CrossRef213
(2009) Decontamination of the Digestive Tract in ICU Patients. New England Journal of Medicine 360:20, 2138-2141
Full Text214
Dale N. Gerding, Colin Broom, Steven P. Gelone. (2009) Clostridium difficile Infection. Infectious Diseases in Clinical Practice 17:3, 161-168
CrossRef215
Jennifer R. O'Connor, Stuart Johnson, Dale N. Gerding. (2009) Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain. Gastroenterology 136:6, 1913-1924
CrossRef216
S. B. Debast, N. Vaessen, A. Choudry, E. A. J. Wiegers-Ligtvoet, R. J. van den Berg, E. J. Kuijper. (2009) Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clinical Microbiology and Infection 15:5, 427-434
CrossRef217
Herbert L. DuPont, Charles D. Ericsson, Michael J. G. Farthing, Sherwood Gorbach, Larry K. Pickering, Lars Rombo, Robert Steffen, Thomas Weinke. (2009) Expert Review of the Evidence Base for Self-Therapy of Travelers’ Diarrhea. Journal of Travel Medicine 16:3, 161-171
CrossRef218
Lori R. Holtz, Marguerite A. Neill, Phillip I. Tarr. (2009) Acute Bloody Diarrhea: A Medical Emergency for Patients of All Ages. Gastroenterology 136:6, 1887-1898
CrossRef219
Sarah Jackson-Rosario, Darin Cowart, Andrew Myers, Rebecca Tarrien, Rodney L. Levine, Robert A. Scott, William Thomas Self. (2009) Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct. JBIC Journal of Biological Inorganic Chemistry 14:4, 507-519
CrossRef220
William R. Jarvis, JoAnn Schlosser, Ashley A. Jarvis, Raymond Y. Chinn. (2009) National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. American Journal of Infection Control 37:4, 263-270
CrossRef221
Alejandro Arteaga, Patricia Santa-Olalla, M. José Sierra, Aurora Limia, Marta Cortés, Carmen Amela. (2009) Riesgo epidémico de la enfermedad asociada a una nueva cepa de Clostridium difficile. Enfermedades Infecciosas y Microbiología Clínica 27:5, 278-284
CrossRef222
Dena Lyras, Jennifer R. O’Connor, Pauline M. Howarth, Susan P. Sambol, Glen P. Carter, Tongted Phumoonna, Rachael Poon, Vicki Adams, Gayatri Vedantam, Stuart Johnson, Dale N. Gerding, Julian I. Rood. (2009) Toxin B is essential for virulence of Clostridium difficile. Nature 458:7242, 1176-1179
CrossRef223
Haihui Huang, Shi Wu, Minggui Wang, Yingyuan Zhang, Hong Fang, Ann-Chatrin Palmgren, Andrej Weintraub, Carl Erik Nord. (2009) Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. International Journal of Antimicrobial Agents 33:4, 339-342
CrossRef224
Gareth C Parkes, Jeremy D Sanderson, Kevin Whelan. (2009) The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. The Lancet Infectious Diseases 9:4, 237-244
CrossRef225
Mary Y. Hu, Kianoosh Katchar, Lorraine Kyne, Seema Maroo, Sanjeev Tummala, Valley Dreisbach, Hua Xu, Daniel A. Leffler, Ciarán P. Kelly. (2009) Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection. Gastroenterology 136:4, 1206-1214
CrossRef226
Philip A. Efron, John E. Mazuski. (2009) Clostridium difficile Colitis. Surgical Clinics of North America 89:2, 483-500
CrossRef227
Philip Toltzis, Jason Kim, Michael Dul, Joan Zoltanski, Sarah Smathers, Theoklis Zaoutis. (2009) Presence of the Epidemic North American Pulsed Field Type 1 Clostridium Difficile Strain in Hospitalized Children. The Journal of Pediatrics 154:4, 607-608
CrossRef228
U. A. Ochsner, S. J. Bell, A. L. O'Leary, T. Hoang, K. C. Stone, C. L. Young, I. A. Critchley, N. Janjic. (2009) Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. Journal of Antimicrobial Chemotherapy 63:5, 964-971
CrossRef229
I. A. Critchley, L. S. Green, C. L. Young, J. M. Bullard, R. J. Evans, M. Price, T. C. Jarvis, J. W. Guiles, N. Janjic, U. A. Ochsner. (2009) Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. Journal of Antimicrobial Chemotherapy 63:5, 954-963
CrossRef230
Karl Weiss. (2009) Clostridium difficile and fluoroquinolones: is there a link?. International Journal of Antimicrobial Agents 33, S29-S32
CrossRef231
Insa Joost, Katja Speck, Mathias Herrmann, Lutz von Müller. (2009) Characterisation of Clostridium difficile isolates by slpA and tcdC gene sequencing. International Journal of Antimicrobial Agents 33, S13-S18
CrossRef232
Robert P. Fagan, David Albesa-Jové, Omar Qazi, Dmitri I. Svergun, Katherine A. Brown, Neil F. Fairweather. (2009) Structural insights into the molecular organization of the S-layer from Clostridium difficile. Molecular Microbiology 71:5, 1308-1322
CrossRef233
John E. Coia. (2009) What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile?. International Journal of Antimicrobial Agents 33, S9-S12
CrossRef234
Michelle M. Merrigan, Susan P. Sambol, Stuart Johnson, Dale N. Gerding. (2009) New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. International Journal of Antimicrobial Agents 33, S46-S50
CrossRef235
P. Gastmeier, D. Weitzel-Kage, M. Behnke, T. Eckmanns. (2009) Surveillance of Clostridium difficile-associated diarrhoea with the German nosocomial infection surveillance system KISS (CDAD-KISS). International Journal of Antimicrobial Agents 33, S19-S23
CrossRef236
Jacques Pepin, Thanh Truc Vo, Marylise Boutros, Eric Marcotte, Sandra Dial, Serge Dubé, Carol-Ann Vasilevsky, Nathalie McFadden, Carlos Patino, Annie-Claude Labbé. (2009) Risk Factors for Mortality Following Emergency Colectomy for Fulminant Clostridium difficile Infection. Diseases of the Colon & Rectum 52:3, 400-405
CrossRef237
N. Salles. (2009) Clostridium difficile: prévalence, conséquences et traitement chez la personne âgée. Les cahiers de l'année gérontologique 1:1, 73-79
CrossRef238
C. Denève, C. Janoir, I. Poilane, C. Fantinato, A. Collignon. (2009) New trends in Clostridium difficile virulence and pathogenesis. International Journal of Antimicrobial Agents 33, S24-S28
CrossRef239
Dale N. Gerding. (2009) Clostridium difficile 30 years on: what has, or has not, changed and why?. International Journal of Antimicrobial Agents 33, S2-S8
CrossRef240
Scott R. Curry, Jane W. Marsh, Kathleen A. Shutt, Carlene A. Muto, Mary M. O’Leary, Melissa I. Saul, A. William Pasculle, Lee H. Harrison. (2009) High Frequency of Rifampin Resistance Identified in an Epidemic Clostridium difficile Clone from a Large Teaching Hospital. Clinical Infectious Diseases 48:4, 425-429
CrossRef241
(2009) Clostridium difficile. New England Journal of Medicine 360:6, 636-638
Full Text242
Joseph A. Sorg, Sean S. Dineen. 2009. Laboratory Maintenance of Clostridium difficile. .
CrossRef243
Christine Schlenker, Christina M. Surawicz. (2009) Emerging infections of the gastrointestinal tract. Best Practice & Research Clinical Gastroenterology 23:1, 89-99
CrossRef244
Donald M. Dumford, Michelle M. Nerandzic, Brittany C. Eckstein, Curtis J. Donskey. (2009) What is on that keyboard? Detecting hidden environmental reservoirs of Clostridium difficile during an outbreak associated with North American pulsed-field gel electrophoresis type 1 strains. American Journal of Infection Control 37:1, 15-19
CrossRef245
Richard L Nelson, Anne Marie Glenny, Fujian Song, Richard L Nelson. 2009. Antimicrobial prophylaxis for colorectal surgery. .
CrossRef246
Kelvin T. Thia, Uma Mahadevan, Brian G. Feagan, Cindy Wong, Alan Cockeram, Alain Bitton, Charles N. Bernstein, William J. Sandborn. (2009) Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: A randomized, double-blind, placebo-controlled pilot study. Inflammatory Bowel Diseases 15:1, 17-24
CrossRef247
Dimitrios P. Kontoyiannis, Russell E. Lewis, Kieren Marr. (2009) The Burden of Bacterial and Viral Infections in Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation 15:1, 128-133
CrossRef248
Lynne V McFarland. (2009) Renewed interest in a difficult disease: Clostridium difficile infections – epidemiology and current treatment strategies. Current Opinion in Gastroenterology 25:1, 24-35
CrossRef249
John G. Bartlett. (2009) New antimicrobial agents for patients with Clostridium difficile infections. Current Infectious Disease Reports 11:1, 21-28
CrossRef250
Haihui Huang, Carl Erik Nord. (2009) Can metronidazole still be used for treatment of Clostridium difficile infections?. Current Infectious Disease Reports 11:1, 3-6
CrossRef251
Erik R. Dubberke, Albert I. Wertheimer. (2009) Review of Current Literature on the Economic Burden of Clostridium difficile Infection • . Infection Control and Hospital Epidemiology 30:1, 57-66
CrossRef252
Tae Jun Byun, Dong Soo Han, Sang Bong Ahn, Hyun Seok Cho, Tae Yeob Kim, Chang Soo Eun, Yong Cheol Jeon, Joo Hyun Sohn, Jung Oak Kang. (2009) Clinical Characteristics and Changing Epidemiology of Clostridium difficile-Associated Disease (CDAD). The Korean Journal of Gastroenterology 54:1, 13
CrossRef253
Kevin W. Garey, Zhi-Dong Jiang, Angelle Bellard, Herbert L. DuPont. (2009) Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study. Journal of Clinical Gastroenterology 43:1, 91-92
CrossRef254
ROBERT E. PETRAS, WENDY L. FRANKEL. 2009. Large Intestine (Colon). , 755-836.
CrossRef255
L. Fenner, R. Frei, M. Gregory, M. Dangel, A. Stranden, A. F. Widmer. (2008) Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006–2007. European Journal of Clinical Microbiology & Infectious Diseases 27:12, 1201-1207
CrossRef256
Mary Y. Hu, Seema Maroo, Lorraine Kyne, Jeffrey Cloud, Sanjeev Tummala, Kianoosh Katchar, Valley Dreisbach, Laura Noddin, Ciarán P. Kelly. (2008) A Prospective Study of Risk Factors and Historical Trends in Metronidazole Failure for Clostridium difficile Infection. Clinical Gastroenterology and Hepatology 6:12, 1354-1360
CrossRef257
M. Raffat Jaber, Snorri Olafsson, Wesley L. Fung, Mark E. Reeves. (2008) Clinical Review of the Management of Fulminant Clostridium difficile Infection. The American Journal of Gastroenterology 103:12, 3195-3203
CrossRef258
Jaime Belmares, Dale N Gerding, Glenn Tillotson, Stuart Johnson. (2008) Measuring the severity of Clostridium difficile infection: implications for management and drug development. Expert Review of Anti-infective Therapy 6:6, 897-908
CrossRef259
Herbert L DuPont, Kevin Garey, Juan-Pablo Caeiro, Zhi-Dong Jiang. (2008) New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Current Opinion in Internal Medicine 7:6, 591-598
CrossRef260
K.W. Garey, S. Sethi, Y. Yadav, H.L. DuPont. (2008) Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. Journal of Hospital Infection 70:4, 298-304
CrossRef261
Sobia Ali, Cyrus P. Tamboli. (2008) Advances in epidemiology and diagnosis of inflammatory bowel diseases. Current Gastroenterology Reports 10:6, 576-584
CrossRef262
D Bobak, L M Arfons, R J Creger, H M Lazarus. (2008) Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?. Bone Marrow Transplantation 42:11, 705-713
CrossRef263
Rhonda KuoLee, Wangxue Chen. (2008) Non-antibiotic strategies for the prevention/treatment of Clostridium difficile infection. Expert Opinion on Therapeutic Patents 18:12, 1395-1403
CrossRef264
David J Riddle, Erik R Dubberke. (2008) Clostridium difficile infection in solid organ transplant recipients. Current Opinion in Organ Transplantation 13:6, 592-600
CrossRef265
J. M. Blondeau. (2008) What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?. Journal of Antimicrobial Chemotherapy 63:2, 238-242
CrossRef266
Abraham Goorhuis, Dennis Bakker, Jeroen Corver, Sylvia B. Debast, Celine Harmanus, Daan W. Notermans, Aldert A. Bergwerff, Frido W. Dekker, Ed J. Kuijper. (2008) Emergence of Clostridium difficile Infection Due to a New Hypervirulent Strain, Polymerase Chain Reaction Ribotype 078. Clinical Infectious Diseases 47:9, 1162-1170
CrossRef267
Joseph Guiles, Ian Critchley, Xicheng Sun. (2008) New agents for Clostridium difficile -associated disease. Expert Opinion on Investigational Drugs 17:11, 1671-1683
CrossRef268
Kelly, Ciarán P., LaMont, J. Thomas, . (2008) Clostridium difficile — More Difficult Than Ever. New England Journal of Medicine 359:18, 1932-1940
Full Text269
Kimberly Lumpkins, Grant V. Bochicchio, Manjari Joshi, Ryan Gens, Kelly Bochicchio, Anne Conway, Stacey Schaub, Thomas Scalea. (2008) Clostridium difficile Infection in Critically Injured Trauma Patients. Surgical Infections 9:5, 497-501
CrossRef270
Erik R. Dubberke, Dale N. Gerding, David Classen, Kathleen M. Arias, Kelly Podgorny, Deverick J. Anderson, Helen Burstin, David P. Calfee, Susan E. Coffin, Victoria Fraser, Frances A. Griffin, Peter Gross, Keith S. Kaye, Michael Klompas, Evelyn Lo, Jonas Marschall, Leonard A. Mermel, Lindsay Nicolle, David A. Pegues, Trish M. Perl, Sanjay Saint, Cassandra D. Salgado, Robert A. Weinstein, Robert Wise, Deborah S. Yokoe. (2008) Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals • . Infection Control and Hospital Epidemiology 29:S1, S81-S92
CrossRef271
Deborah S. Yokoe, Leonard A. Mermel, Deverick J. Anderson, Kathleen M. Arias, Helen Burstin, David P. Calfee, Susan E. Coffin, Erik R. Dubberke, Victoria Fraser, Dale N. Gerding, Frances A. Griffin, Peter Gross, Keith S. Kaye, Michael Klompas, Evelyn Lo, Jonas Marschall, Lindsay Nicolle, David A. Pegues, Trish M. Perl, Kelly Podgorny, Sanjay Saint, Cassandra D. Salgado, Robert A. Weinstein, Robert Wise, David Classen. (2008) Executive Summary: A Compendium of Strategies to Prevent Healthcare‐Associated Infections in Acute Care Hospitals • . Infection Control and Hospital Epidemiology 29:S1, S12-S21
CrossRef272
Aldo A. M. Lima, Nilberto R. F. Nascimento, Guodong D. Fang, Peter Yotseff, M. H. Toyama, Richard L. Guerrant, Manassés C. Fonteles. (2008) Role of phospholipase A 2 and tyrosine kinase in Clostridium difficile toxin A-induced disruption of epithelial integrity, histologic inflammatory damage and intestinal secretion. Journal of Applied Toxicology 28:7, 849-857
CrossRef273
Kevin W. Garey, Zhi-Dong Jiang, Yashoo Yadav, Bridget Mullins, Keith Wong, Herbert L. Dupont. (2008) Peripartum Clostridium difficile infection: case series and review of the literature. American Journal of Obstetrics and Gynecology 199:4, 332-337
CrossRef274
Mazen Issa, Ashwin N. Ananthakrishnan, David G. Binion. (2008) Clostridium difficile and inflammatory bowel disease. Inflammatory Bowel Diseases 14:10, 1432-1442
CrossRef275
Herbert L DuPont, Kevin Garey, Juan-Pablo Caeiro, Zhi-Dong Jiang. (2008) New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Current Opinion in Infectious Diseases 21:5, 500-507
CrossRef276
K.W. Garey, T.K. Dao-Tran, Z.D. Jiang, M.P. Price, L.O. Gentry, H.L. DuPont. (2008) A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. Journal of Hospital Infection 70:2, 142-147
CrossRef277
Mar Sánchez‐Somolinos, Luis Alcalá, Teresa Peláez, Mercedes Marín, Adoración Martín, Pilar Catalán, Emilio Bouza. (2008) High Levels of Resistance to Fluoroquinolones among Clostridium difficile Isolates in a Spanish Hospital. Clinical Infectious Diseases 47:6, 818-822
CrossRef278
Joshua L. Hermsen, Cosmin Dobrescu, Kenneth A. Kudsk. (2008) Clostridium difficile Infection: A Surgical Disease in Evolution. Journal of Gastrointestinal Surgery 12:9, 1512-1517
CrossRef279
B. KLARIN, M. WULLT, I. PALMQUIST, G. MOLIN, A. LARSSON, B. JEPPSSON. (2008) Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiologica Scandinavica 52:8, 1096-1102
CrossRef280
P. A. Sutton, S. Li, J. Webb, K. Solomon, J. Brazier, Y. R. Mahida. (2008) Essential role of toxin A in C. difficile 027 and reference strain supernatant-mediated disruption of Caco-2 intestinal epithelial barrier function. Clinical & Experimental Immunology 153:3, 439-447
CrossRef281
Catherine E Murphy, Alison M Stevens, Nicholas Ferrentino, Bruce A Crookes, James C Hebert, Carter B Freiburg, Jill A Rebuck. (2008) Frequency of Inappropriate Continuation of Acid Suppressive Therapy After Discharge in Patients Who Began Therapy in the Surgical Intensive Care Unit. Pharmacotherapy 28:8, 968-976
CrossRef282
John M. Boyce, Nancy L. Havill, Jonathan A. Otter, L. Clifford McDonald, Nicholas M. T. Adams, Timothea Cooper, Angela Thompson, Lois Wiggs, George Killgore, Allison Tauman, Judith Noble-Wang. (2008) Impact of Hydrogen Peroxide Vapor Room Decontamination on Clostridium difficile Environmental Contamination and Transmission in a Healthcare Setting. Infection Control and Hospital Epidemiology 29:8, 723-729
CrossRef283
U. Stiefel, M. M. Nerandzic, P. Koski, C. J. Donskey. (2008) Orally administered -lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. Journal of Antimicrobial Chemotherapy 62:5, 1105-1108
CrossRef284
Wafa N. Al‐Nassir, Ajay K. Sethi, Michelle M. Nerandzic, Greg S. Bobulsky, Robin L. P. Jump, Curtis J. Donskey. (2008) Comparison of Clinical and Microbiological Response to Treatment of Clostridium difficile –Associated Disease with Metronidazole and Vancomycin. Clinical Infectious Diseases 47:1, 56-62
CrossRef285
Christoph von Eichel-Streiber, Veit Braun. (2008) Das difficile Clostridium / The difficile Clostridium. LaboratoriumsMedizin 32:4, 219-234
CrossRef286
Brandon P. Verdoorn, Robert Orenstein, John W. Wilson, Lynn L. Estes, Randy F. Wendt, Cathy D. Schleck, William S. Harmsen, Lisa M. Nyre, Robin Patel. (2008) Effect of Telephoned Notification of Positive Clostridium difficile Test Results on the Time to the Ordering of Antimicrobial Therapy. Infection Control and Hospital Epidemiology 29:7, 658-660
CrossRef287
Jennifer Peppe, Andrew Porzio, David M. Davidson. (2008) A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial. British Journal of Clinical Pharmacology 66:1, 102-109
CrossRef288
T. Dingle, S. Wee, G. L Mulvey, A. Greco, E. N Kitova, J. Sun, S. Lin, J. S Klassen, M. M Palcic, K. K S Ng, G. D Armstrong. (2008) Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile. Glycobiology 18:9, 698-706
CrossRef289
T. I. I. van der Kooi, M. Koningstein, A. Lindemans, D. W. Notermans, E. Kuijper, R. van den Berg, H. Boshuizen, P. M. G. Filius, S. van den Hof. (2008) Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027. Journal of Medical Microbiology 57:6, 709-716
CrossRef290
R. A. Stabler, L. F. Dawson, L. T. H. Phua, B. W. Wren. (2008) Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. Journal of Medical Microbiology 57:6, 771-775
CrossRef291
T. Giesemann, M. Egerer, T. Jank, K. Aktories. (2008) Processing of Clostridium difficile toxins. Journal of Medical Microbiology 57:6, 690-696
CrossRef292
B. Dupuy, R. Govind, A. Antunes, S. Matamouros. (2008) Clostridium difficile toxin synthesis is negatively regulated by TcdC. Journal of Medical Microbiology 57:6, 685-689
CrossRef293
Nadine G. Rouphael, Judith A. O'Donnell, Julu Bhatnagar, Felicia Lewis, Philip M. Polgreen, Susan Beekmann, Jeannette Guarner, George E. Killgore, Becky Coffman, Jennifer Campbell, Sherif R. Zaki, L. Clifford McDonald. (2008) Clostridium difficile–associated diarrhea: an emerging threat to pregnant women. American Journal of Obstetrics and Gynecology 198:6, 635.e1-635.e6
CrossRef294
Geoffrey C. Nguyen, Gilaad G. Kaplan, Mary L. Harris, Steven R. Brant. (2008) A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients. The American Journal of Gastroenterology 103:6, 1443-1450
CrossRef295
C. Deneve, C. Delomenie, M.-C. Barc, A. Collignon, C. Janoir. (2008) Antibiotics involved in Clostridium difficile-associated disease increase colonization factor gene expression. Journal of Medical Microbiology 57:6, 732-738
CrossRef296
Claribel P. Taylor, Sanjeev Tummala, Deborah Molrine, Lisa Davidson, Richard J. Farrell, Anthony Lembo, Patricia L. Hibberd, Israel Lowy, Ciaran P. Kelly. (2008) Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 26:27-28, 3404-3409
CrossRef297
J. E. Emerson, R. A. Stabler, B. W. Wren, N. F. Fairweather. (2008) Microarray analysis of the transcriptional responses of Clostridium difficile to environmental and antibiotic stress. Journal of Medical Microbiology 57:6, 757-764
CrossRef298
L. F. Dawson, R. A. Stabler, B. W. Wren. (2008) Assessing the role of p-cresol tolerance in Clostridium difficile. Journal of Medical Microbiology 57:6, 745-749
CrossRef299
Bayan Missaghi, August J. Valenti, Robert C. Owens. (2008) Clostridium difficile infection: A critical overview. Current Infectious Disease Reports 10:3, 165-173
CrossRef300
Thomas Jank, Klaus Aktories. (2008) Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends in Microbiology 16:5, 222-229
CrossRef301
Robert C. Owens. (2008) Antimicrobial stewardship: concepts and strategies in the 21st century. Diagnostic Microbiology and Infectious Disease 61:1, 110-128
CrossRef302
Maja Rupnik. (2008) Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiology Reviews 32:3, 541-555
CrossRef303
R.-P. Vonberg, E. J. Kuijper, M. H. Wilcox, F. Barbut, P. Tüll, P. Gastmeier, , P. J. van den Broek, A. Colville, B. Coignard, T. Daha, S. Debast, B. I. Duerden, S. van den Hof, T. van der Kooi, H. J. H. Maarleveld, E. Nagy, D. W. Notermans, J. O’Driscoll, B. Patel, S. Stone, C. Wiuff. (2008) Infection control measures to limit the spread of Clostridium difficile. Clinical Microbiology and Infection 14:s5, 2-20
CrossRef304
H. L. DUPONT. (2008) Systematic review: prevention of travellers’ diarrhoea. Alimentary Pharmacology & Therapeutics 27:9, 741-751
CrossRef305
John K Crane, Kazi M Hoque. (2008) Zinc for Infectious Diarrhea in Developed Countries: Should We Be Sprinkling Our Own Lawns?. Journal of Pediatric Gastroenterology and Nutrition 46:5, 484-485
CrossRef306
A. R. F. Barreto, I. C. Cavalcante, M. V. Castro, A. F. T. A. Junqueira, M. R. Vale, R. A. Ribeiro, M. H. L. P. Souza, G. A. C. Brito. (2008) Fucoidin Prevents Clostridium difficile Toxin-A-Induced Ileal Enteritis in Mice. Digestive Diseases and Sciences 53:4, 990-996
CrossRef307
Naomi P. O’Grady, Philip S. Barie, John G. Bartlett, Thomas Bleck, Karen Carroll, Andre C. Kalil, Peter Linden, Dennis G. Maki, David Nierman, William Pasculle, Henry Masur. (2008) Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Critical Care Medicine 36:4, 1330-1349
CrossRef308
Michael Gerber, Grit Ackermann. (2008) OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opinion on Investigational Drugs 17:4, 547-553
CrossRef309
Daniel M. Musher, Saima Aslam. (2008) Treatment of Clostridium Difficile Colitis in the Critical Care Setting. Critical Care Clinics 24:2, 279-291
CrossRef310
J. B. Kaper, M. A. Karmali. (2008) The continuing evolution of a bacterial pathogen. Proceedings of the National Academy of Sciences 105:12, 4535-4536
CrossRef311
M. T. Hecker, M. M. Riggs, C. K. Hoyen, C. Lancioni, C. J. Donskey. (2008) Recurrent Infection with Epidemic Clostridium difficile in a Peripartum Woman Whose Infant Was Asymptomatically Colonized with the Same Strain. Clinical Infectious Diseases 46:6, 956-957
CrossRef312
K. Blanckaert, B. Coignard, B. Grandbastien, P. Astagneau, F. Barbut. (2008) Actualités sur les infections à Clostridium difficile. La Revue de Médecine Interne 29:3, 209-214
CrossRef313
David A. Bobak. (2008) The molecular pathogenesis of Clostridium difficile-associated disease. Current Infectious Disease Reports 10:2, 111-115
CrossRef314
Jeyabarathy Ganeshapillai, Evguenii Vinogradov, Joyce Rousseau, J. Scott Weese, Mario A. Monteiro. (2008) Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydrate Research 343:4, 703-710
CrossRef315
Preeta K. Kutty, Stephen R. Benoit, Christopher W. Woods, Arlene C. Sena, Susanna Naggie, Joyce Frederick, John Engemann, Sharon Evans, Brian C. Pien, Shailendra N. Banerjee, Jeffery Engel, L. Clifford McDonald. (2008) Assessment of Clostridium difficile –Associated Disease Surveillance Definitions, North Carolina, 2005 • . Infection Control and Hospital Epidemiology 29:3, 197-202
CrossRef316
Leanne B. Gasink, Ebbing Lautenbach. (2008) Prevention and Treatment of Health Care–Acquired Infections. Medical Clinics of North America 92:2, 295-313
CrossRef317
J. A. Paladino, J. J. Schentag. (2008) The Economics of Clostridium difficile-Associated Disease for Providers and Payers. Clinical Infectious Diseases 46:4, 505-506
CrossRef318
E. R. Dubberke, K. A. Reske, M. A. Olsen, L. C. McDonald, V. J. Fraser. (2008) Short- and Long-Term Attributable Costs of Clostridium difficile-Associated Disease in Nonsurgical Inpatients. Clinical Infectious Diseases 46:4, 497-504
CrossRef319
Michael J. Wood, Neil Hyman, James C. Hebert, Hagen Blaszyk. (2008) Catastrophic Clostridium difficile Enteritis in a Pelvic Pouch Patient: Report of a Case. Journal of Gastrointestinal Surgery 12:2, 350-352
CrossRef320
O. Leiß, L. Bader, M. Mielke, M. Exner. (2008) Fünf Jahre Empfehlungen der Kommission für Krankenhaushygiene zur Aufbereitung flexibler Endoskope. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 51:2, 211-220
CrossRef321
Abhishek Deshpande, Chaitanya Pant, Anil Jain, Thomas G. Fraser, David D. K. Rolston. (2008) Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Current Medical Research and Opinion 24:2, 329-333
CrossRef322
B. Connor. (2008) Traveler's Diarrhea Chemoprophylaxis: An Alternative Recommendation. Clinical Infectious Diseases 46:3, 475-476
CrossRef323
Anjana Pillai, Richard L Nelson, Anjana Pillai. 2008. Probiotics for treatment of Clostridium difficile-associated colitis in adults. .
CrossRef324
Robert C. Owens, Jr., Curtis J. Donskey, Robert P. Gaynes, Vivian G. Loo, Carlene A. Muto. (2008) Antimicrobial‐Associated Risk Factors for Clostridium difficile Infection. Clinical Infectious Diseases 46:s1, S19-S31
CrossRef325
Dale N. Gerding, Carlene A. Muto, Robert C. Owens, Jr.. (2008) Treatment of Clostridium difficile Infection. Clinical Infectious Diseases 46:s1, S32-S42
CrossRef326
Yuichi KOIZUMI, Takeshi KIMURA, Shigekatsu HATANAKA, Misato KADOTANI, Yoichi TAKAHASHI. (2008) Japanese Journal of Environmental Infections 23:3, 175-180
CrossRef327
Roger Baxter, G. Thomas Ray, Bruce H. Fireman. (2008) Case‐Control Study of Antibiotic Use and Subsequent Clostridium difficile –Associated Diarrhea in Hospitalized Patients • . Infection Control and Hospital Epidemiology 29:1, 44-50
CrossRef328
Lynne V McFarland. (2008) Update on the changing epidemiology of Clostridium difficile-associated disease. Nature Clinical Practice Gastroenterology & Hepatology 5:1, 40-48
CrossRef329
Paola Mastrantonio, Fabrizio Barbanti, Patrizia Spigaglia. (2008) Hypervirulent antibiotic-resistant Clostridium difficile in Europe. Microbial Ecology in Health and Disease 20:4, 210-212
CrossRef330
Marion Buyse, Philippe Marteau, François Gimenez†, Olivier Goulet, Philippe Marteau. 2008. Traitement des diarrhées. , 269-289.
CrossRef331
Nadia Razaq, Susan Sambol, Kristin Nagaro, Walter Zukowski, Adam Cheknis, Stuart Johnson, Dale N. Gerding. (2007) Infection of Hamsters with Historical and Epidemic BI Types of Clostridium difficile. The Journal of Infectious Diseases 196:12, 1813-1819
CrossRef332
E. R. Dubberke, K. A. Reske, Y. Yan, M. A. Olsen, L. C. McDonald, V. J. Fraser. (2007) Clostridium difficile--Associated Disease in a Setting of Endemicity: Identification of Novel Risk Factors. Clinical Infectious Diseases 45:12, 1543-1549
CrossRef333
Jacques Pépin, Louis Valiquette, Sandra Gagnon, Sophie Routhier, Isabel Brazeau. (2007) Outcomes of Clostridium difficile-Associated Disease Treated With Metronidazole or Vancomycin Before and After the Emergence of NAP1/027. The American Journal of Gastroenterology 102:12, 2781-2788
CrossRef334
Jane D. Siegel, Emily Rhinehart, Marguerite Jackson, Linda Chiarello. (2007) 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. American Journal of Infection Control 35:10, S65-S164
CrossRef335
Jaime Belmares, Dale N. Gerding, Jorge P. Parada, Scott Miskevics, Frances Weaver, Stuart Johnson. (2007) Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. Journal of Infection 55:6, 495-501
CrossRef336
L. Dubreuil. (2007) Clostridium difficile : de O’Toole à 027. Antibiotiques 9:4, 268-273
CrossRef337
Marc Zerey, B. Lauren Paton, Amy E. Lincourt, Keith S. Gersin, Kent W. Kercher, B. Todd Heniford. (2007) The Burden of Clostridium difficile in Surgical Patients in the United States. Surgical Infections 8:6, 557-566
CrossRef338
C. Cattoen, A. Boruchowicz. (2007) Diagnostic et prise en charge thérapeutique des infections à Clostridium difficile. Antibiotiques 9:4, 278-283
CrossRef339
Robert C. Owens, August J. Valenti, Mark H. Wilcox. 2007. Clostridium difficile Infection: Overview and Update with a Focus on Antimicrobial Resistance as a Risk Factor. , 183-218.
CrossRef340
Robert C Owens. 2007. Antimicrobial Stewardship: Rationale for and Practical Considerations of Programmatic Institutional Efforts to Optimize Antimicrobial Use. , 261-300.
CrossRef341
L. C. McDonald. (2007) Confronting Clostridium difficile in Inpatient Health Care Facilities. Clinical Infectious Diseases 45:10, 1274-1276
CrossRef342
C. A. Muto, M. K. Blank, J. W. Marsh, E. N. Vergis, M. M. O'Leary, K. A. Shutt, A. W. Pasculle, M. Pokrywka, J. G. Garcia, K. Posey, T. L. Roberts, B. A. Potoski, G. E. Blank, R. L. Simmons, P. Veldkamp, L. H. Harrison, D. L. Paterson. (2007) Control of an Outbreak of Infection with the Hypervirulent Clostridium difficile BI Strain in a University Hospital Using a Comprehensive "Bundle" Approach. Clinical Infectious Diseases 45:10, 1266-1273
CrossRef343
F. Barbut, P. Mastrantonio, M. Delmée, J. Brazier, E. Kuijper, I. Poxton, . (2007) Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clinical Microbiology and Infection 13:11, 1048-1057
CrossRef344
S. Paltansing, R. J. van den Berg, R. A. Guseinova, C. E. Visser, E. R. van der Vorm, E. J. Kuijper. (2007) Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clinical Microbiology and Infection 13:11, 1058-1064
CrossRef345
Luis A. Marcos, Herbert L. DuPont. (2007) Advances in defining etiology and new therapeutic approaches in acute diarrhea. Journal of Infection 55:5, 385-393
CrossRef346
Lacey Benson, Xiaoyan Song, Joseph Campos, Nalini Singh. (2007) Changing Epidemiology of Clostridium difficile –Associated Disease in Children • . Infection Control and Hospital Epidemiology 28:11, 1233-1235
CrossRef347
Adam L. Cohen, Julu Bhatnagar, Sarah Reagan, Suzanne B. Zane, Marisa A. DʼAngeli, Marc Fischer, George Killgore, Tao Sheng Kwan-Gett, David B. Blossom, Wun-Ju Shieh, Jeannette Guarner, John Jernigan, Jeffrey S. Duchin, Sherif R. Zaki, L Clifford McDonald. (2007) Toxic Shock Associated With Clostridium sordellii and Clostridium perfringens After Medical and Spontaneous Abortion. Obstetrics & Gynecology 110:5, 1027-1033
CrossRef348
L. R. Peterson, R. U. Manson, S. M. Paule, D. M. Hacek, A. Robicsek, R. B. Thomson, K. L. Kaul. (2007) Detection of Toxigenic Clostridium difficile in Stool Samples by Real-Time Polymerase Chain Reaction for the Diagnosis of C. difficile-Associated Diarrhea. Clinical Infectious Diseases 45:9, 1152-1160
CrossRef349
Judith A. O’Brien, Betsy J. Lahue, J. Jaime Caro, David M. Davidson. (2007) The Emerging Infectious Challenge of Clostridium difficile –Associated Disease in Massachusetts Hospitals: Clinical and Economic Consequences • . Infection Control and Hospital Epidemiology 28:11, 1219-1227
CrossRef350
C. A. Muto. (2007) Asymptomatic Clostridium difficile Colonization: Is This the Tip of Another Iceberg?. Clinical Infectious Diseases 45:8, 999-1000
CrossRef351
M. M. Riggs, A. K. Sethi, T. F. Zabarsky, E. C. Eckstein, R. L. P. Jump, C. J. Donskey. (2007) Asymptomatic Carriers Are a Potential Source for Transmission of Epidemic and Nonepidemic Clostridium difficile Strains among Long-Term Care Facility Residents. Clinical Infectious Diseases 45:8, 992-998
CrossRef352
Christos Gougoulias, Kieran M. Tuohy, Glenn R. Gibson. (2007) Dietary-based gut flora modulation against Clostridium difficile onset. Food Science & Technology Bulletin: Functional Foods 4:4, 31-41
CrossRef353
Ed J Kuijper, Jaap T van Dissel, Mark H Wilcox. (2007) Clostridium difficile: changing epidemiology and new treatment options. Current Opinion in Internal Medicine 6:5, 479-486
CrossRef354
B. Razavi, A. Apisarnthanarak, L. M. Mundy. (2007) Clostridium difficile: Emergence of Hypervirulence and Fluoroquinolone Resistance. Infection 35:5, 300-307
CrossRef355
A. Goorhuis, T. Van der Kooi, N. Vaessen, F. W. Dekker, R. Van den Berg, C. Harmanus, S. van den Hof, D. W. Notermans, E. J. Kuijper. (2007) Spread and Epidemiology of Clostridium difficile Polymerase Chain Reaction Ribotype 027/Toxinotype III in The Netherlands. Clinical Infectious Diseases 45:6, 695-703
CrossRef356
E. Sawabe, H. Kato, K. Osawa, T. Chida, N. Tojo, Y. Arakawa, N. Okamura. (2007) Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. European Journal of Clinical Microbiology & Infectious Diseases 26:10, 695-703
CrossRef357
Christoph Schmidt, Birgit Löffler, Grit Ackermann. (2007) Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagnostic Microbiology and Infectious Disease 59:1, 1-5
CrossRef358
Teresa Pareja Sierra, Mercedes Hornillos Calvo. (2007) Factores epidemiológicos, clínicos y analíticos asociados a diarrea por Clostridium difficile en población anciana hospitalizada. Estudio de casos y controles. Revista Española de Geriatría y Gerontología 42:5, 257-262
CrossRef359
Robert C. Owens, August J. Valenti. (2007) Clostridium difficile-Associated Disease in the New Millennium. Infectious Diseases in Clinical Practice 15:5, 299-315
CrossRef360
M. A. Miller. (2007) Clinical Management of Clostridium difficile-Associated Disease. Clinical Infectious Diseases 45:Supplement 2, S122-S128
CrossRef361
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack. (2007) Intensive Session: New Approaches to Medical Issues in Long-Term Care. Journal of the American Medical Directors Association 8:7, 421-433
CrossRef362
Tin Han Htwe, Adnan Mushtaq, Sherry B. Robinson, Richard B. Rosher, Nancy Khardori. (2007) Infection in the Elderly. Infectious Disease Clinics of North America 21:3, 711-743
CrossRef363
Farrin A. Manian, Sangita Aradhyula, Sandy Greisnauer, Diane Senkel, Janice Setzer, Michele Wiechens, P Lynn Meyer. (2007) Is It Clostridium difficile Infection or Something Else? A Case-control Study of 352 Hospitalized Patients With New-onset Diarrhea. Southern Medical Journal 100:8, 782-786
CrossRef364
D. B. SCHEURER, L. S. HICKS, E. F. COOK, J. L. SCHNIPPER. (2007) Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort. Epidemiology and Infection 135:06, 1010
CrossRef365
Warren N. Fawley, Sarah Underwood, Jane Freeman, Simon D. Baines, Katie Saxton, Keith Stephenson, Robert C. Owens, Jr., Mark H. Wilcox. (2007) Efficacy of Hospital Cleaning Agents and Germicides Against Epidemic Clostridium difficile Strains • . Infection Control and Hospital Epidemiology 28:8, 920-925
CrossRef366
Ciaran P. Kelly. (2007) Playing Host to the Difficult Clostridium. Clinical Gastroenterology and Hepatology 5:8, 912-914
CrossRef367
F. A. Zar, S. R. Bakkanagari, K. M. L. S. T. Moorthi, M. B. Davis. (2007) A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease Severity. Clinical Infectious Diseases 45:3, 302-307
CrossRef368
Richard L Nelson, Richard L Nelson. 2007. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. .
CrossRef369
D. B. Blossom, L. C. McDonald. (2007) The Challenges Posed by Reemerging Clostridium difficile Infection. Clinical Infectious Diseases 45:2, 222-227
CrossRef370
George I. Tsourous, Leonidas G. Raftopoulos, Eleni E. Kafe, Eleftherios K. Manoleris, Kostas P. Makaritsis, Sotirios G. Pinis. (2007) A case of pseudomembranous colitis presenting with massive ascites. European Journal of Internal Medicine 18:4, 328-330
CrossRef371
Susana Matamouros, Patrick England, Bruno Dupuy. (2007) Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Molecular Microbiology 64:5, 1274-1288
CrossRef372
Erik R. Dubberke, Kimberly A. Reske, Judith Noble-Wang, Angela Thompson, George Killgore, Jennie Mayfield, Bernard Camins, Keith Woeltje, Jay R. McDonald, L. Clifford McDonald, Victoria J. Fraser. (2007) Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. American Journal of Infection Control 35:5, 315-318
CrossRef373
Christiane G. Frick, Martina Richtsfeld, Nita D. Sahani, Masao Kaneki, Manfred Blobner, J A. Jeevendra Martyn. (2007) Long-term Effects of Botulinum Toxin on Neuromuscular Function. Anesthesiology 106:6, 1139-1146
CrossRef374
Sarah P. Hammond, Lindsey R. Baden. (2007) Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. Current Hematologic Malignancy Reports 2:2, 97-103
CrossRef375
S.K. Rampini, B. Lüthi, C. Ruef, R.F. Speck. (2007) Clostridium difficile assoziierter Durchfall. Der Gastroenterologe 2:3, 170-178
CrossRef376
John G. Bartlett. (2007) Clostridium difficile. Journal of Clinical Gastroenterology 41:Supplement 1, S24-S29
CrossRef377
Lynne V. McFarland, Henry W. Beneda, Jill E. Clarridge, Gregory J. Raugi. (2007) Implications of the changing face of Clostridium difficile disease for health care practitioners. American Journal of Infection Control 35:4, 237-253
CrossRef378
Ana P. P. Alcides, Jon S. Brazier, Leandro J. F. Pinto, Ilana T. Balassiano, Renata F. Boente, Geraldo R. Paula, Eliane O. Ferreira, Kátia E. S. Avelar, Karla R. Miranda, M. Candida S. Ferreira, Regina M. C. P. Domingues. (2007) New PCR ribotypes of Clostridium difficile detected in children in Brazil. Antonie van Leeuwenhoek 92:1, 53-59
CrossRef379
Jeffrey Cloud, Ciaran P Kelly. (2007) Update on Clostridium difficile associated disease. Current Opinion in Internal Medicine 6:2, 131-136
CrossRef380
Herbert L. Dupont, Zhi–Dong Jiang, Jaime Belkind–Gerson, Pablo C. Okhuysen, Charles D. Ericsson, Shi Ke, David B. Huang, Margaret W. Dupont, Javier A. Adachi, F. Javier De La Cabada, David N. Taylor, Sridvya Jaini, Francisco Martinez Sandoval. (2007) Treatment of Travelers’ Diarrhea: Randomized Trial Comparing Rifaximin, Rifaximin Plus Loperamide, and Loperamide Alone. Clinical Gastroenterology and Hepatology 5:4, 451-456
CrossRef381
Joseph P. Mazzie, Sean R. Wilson, Michael A. Sadler, Michael Khalili, Bruce R. Javors, Shiobhan R. Weston, Douglas S. Katz. (2007) Imaging of Gastrointestinal Tract Infection. Seminars in Roentgenology 42:2, 102-116
CrossRef382
Gonzalo A. del Real, Mark E. Rose, Maria T. Ramirez-Atamoros, Jeffrey Hammel, Steven M. Gordon, Alejandro C. Arroliga, Mercedes E. Arroliga. (2007) Penicillin skin testing in patients with a history of β-lactam allergy. Annals of Allergy, Asthma & Immunology 98:4, 355-359
CrossRef383
&NA;. (2007) Treatment of Clostridium difficile–Associated Disease (CDAD). Obstetrics & Gynecology 109:4, 993-995
CrossRef384
Jessica Reineke, Stefan Tenzer, Maja Rupnik, Andreas Koschinski, Oliver Hasselmayer, André Schrattenholz, Hansjörg Schild, Christoph von Eichel-Streiber. (2007) Autocatalytic cleavage of Clostridium difficile toxin B. Nature 446:7134, 415-419
CrossRef385
Perry Hookman, Jamie S. Barkin. (2007) Review: Clostridium difficile-Associated Disorders/Diarrhea and Clostridium difficile Colitis: The Emergence of a More Virulent Era. Digestive Diseases and Sciences 52:4, 1071-1075
CrossRef386
Robert C. Owens, Paul G. Ambrose. (2007) Antimicrobial stewardship and the role of pharmacokinetics–pharmacodynamics in the modern antibiotic era. Diagnostic Microbiology and Infectious Disease 57:3, S77-S83
CrossRef387
Charles Linker. (2007) The role of autologous transplantation for acute myeloid leukemia in first and second remission. Best Practice & Research Clinical Haematology 20:1, 77-84
CrossRef388
William J. Tremaine. (2007) Inflammatory Bowel Disease and Clostridium difficile–Associated Diarrhea: A Growing Problem. Clinical Gastroenterology and Hepatology 5:3, 310-311
CrossRef389
Joseph F. Rodemann, Erik R. Dubberke, Kimberly A. Reske, Da Hea Seo, Christian D. Stone. (2007) Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 5:3, 339-344
CrossRef390
Amy Pakyz. (2007) A Case of Recurrent Clostridium difficile Diarrhea. The Consultant Pharmacist 22:3, 249-253
CrossRef391
Mazen Issa, Aravind Vijayapal, Mary Beth Graham, Dawn B. Beaulieu, Mary F. Otterson, Sarah Lundeen, Susan Skaros, Lydia R. Weber, Richard A. Komorowski, Josh F. Knox, Jeanne Emmons, Jasmohan S. Bajaj, David G. Binion. (2007) Impact of Clostridium difficile on Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 5:3, 345-351
CrossRef392
H. Rüssmann, K. Panthel, R.-C. Bader, C. Schmitt, R. Schaumann. (2007) Evaluation of three rapid assays for detection of Clostridium difficile toxin A and toxin B in stool specimens. European Journal of Clinical Microbiology & Infectious Diseases 26:2, 115-119
CrossRef393
Frederic Barbut, Beatrice Gariazzo, Laetitia Bonne, Valerie Lalande, Beatrice Burghoffer, Ralucca Luiuz, Jean‐Claude Petit. (2007) Clinical Features of Clostridium difficile –Associated Infections and Molecular Characterization of Strains: Results of a Retrospective Study, 2000‐2004 • . Infection Control and Hospital Epidemiology 28:2, 131-139
CrossRef394
Priscilla Biller, Beth Shank, Leah Lind, Meghan Brennan, Lisa Tkatch, George Killgore, Angela Thompson, L. Clifford McDonald. (2007) Moxifloxacin Therapy as a Risk Factor for Clostridium difficile –Associated Disease During an Outbreak: Attempts to Control a New Epidemic Strain • . Infection Control and Hospital Epidemiology 28:2, 198-201
CrossRef395
Fran??ois Lamontagne, Annie-Claude Labb??, Olivier Haeck, Olivier Lesur, Mathieu Lalancette, Carlos Patino, Martine Leblanc, Michel Laverdi??re, Jacques P??pin. (2007) Impact of Emergency Colectomy on Survival of Patients With Fulminant Clostridium difficile Colitis During an Epidemic Caused by a Hypervirulent Strain. Annals of Surgery 245:2, 267-272
CrossRef396
Steven J. Lawrence, Laura A. Puzniak, Brooke N. Shadel, Kathleen N. Gillespie, Marin H. Kollef, Linda M. Mundy. (2007) Clostridium difficile in the Intensive Care Unit: Epidemiology, Costs, and Colonization Pressure • . Infection Control and Hospital Epidemiology 28:2, 123-130
CrossRef397
Philip M. Polgreen, Yi Yi Chen, Joseph E. Cavanaugh, Melissa Ward, Stacy Coffman, Douglas B. Hornick, Daniel J. Diekema, Loreen A. Herwaldt. (2007) An Outbreak of Severe Clostridium difficile –Associated Disease Possibly Related to Inappropriate Antimicrobial Therapy for Community‐Acquired Pneumonia • . Infection Control and Hospital Epidemiology 28:2, 212-214
CrossRef398
Dale N. Gerding. (2007) New Definitions Will Help, but Cultures are Critical for Resolving Unanswered Questions About Clostridium difficile • . Infection Control and Hospital Epidemiology 28:2, 113-115
CrossRef399
L. Clifford McDonald, Bruno Coignard, Erik Dubberke, Xiaoyan Song, Teresa Horan, Preeta K. Kutty, . (2007) Recommendations for Surveillance of Clostridium difficile –Associated Disease • . Infection Control and Hospital Epidemiology 28:2, 140-145
CrossRef400
B. Hubert, V. G. Loo, A.-M. Bourgault, L. Poirier, A. Dascal, E. Fortin, M. Dionne, M. Lorange. (2007) A Portrait of the Geographic Dissemination of the Clostridium difficile North American Pulsed-Field Type 1 Strain and the Epidemiology of C. difficile-Associated Disease in Quebec. Clinical Infectious Diseases 44:2, 238-244
CrossRef401
M.F. Price, T. Dao-Tran, K.W. Garey, G. Graham, L.O. Gentry, L. Dhungana, H.L. DuPont. (2007) Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. Journal of Hospital Infection 65:1, 42-46
CrossRef402
Herbert L. DuPont, Robert Haake, David N. Taylor, Charles D. Ericsson, Zhi-Dong Jiang, Pablo C Okhuysen, Robert Steffen. (2007) Rifaximin Treatment of Pathogen-Negative Travelers' Diarrhea. Journal of Travel Medicine 14:1,
CrossRef403
Christina M. Surawicz. (2007) Antibiotics and Clostridium difficile: Cause and Cure. Journal of Clinical Gastroenterology 41:1, 1-2
CrossRef404
J.A. Stockman. (2007) An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile. Yearbook of Pediatrics 2007, 232-234
CrossRef405
Edgar C Boedeker. (2007) Gut microbes, the innate immune system and inflammatory bowel disease: location, location, location. Current Opinion in Gastroenterology 23:1, 1-3
CrossRef406
Mihaela Batke, Marcus Zervos, Barbara Robinson-Dunn, Ann L. Silverman. (2007) Clostridium difficile is the Most Common Identifiable Cause of Infectious Colitis. Infectious Diseases in Clinical Practice 15:1, 49-53
CrossRef407
Robert C Owens. (2007) Clostridium difficile-Associated Disease. Drugs 67:4, 487-502
CrossRef408
D. O. Lowe, M. M. Mamdani, A. Kopp, D. E. Low, D. N. Juurlink. (2006) Proton Pump Inhibitors and Hospitalization for Clostridium Difficile--Associated Disease: A Population-Based Study. Clinical Infectious Diseases 43:10, 1272-1276
CrossRef409
Leonard Leibovici, Mical Paul, Michael Cullen, Giampaolo Bucaneve, Anat Gafter-Gvili, Abigail Fraser, Winfried V. Kern. (2006) Antibiotic prophylaxis in neutropenic patients. Cancer 107:8, 1743-1751
CrossRef410
Mary E. Wilson. (2006) Editorial Commentary: Clostridium difficile and Childhood Diarrhea: Cause, Consequence, or Confounder. Clinical Infectious Diseases 43:7, 814-816
CrossRef411
E. J. Kuijper, B. Coignard, P. Tull, , . (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clinical Microbiology and Infection 12:s6, 2-18
CrossRef412
Jacques Pepin. (2006) Editorial Commentary: Improving the Treatment of Clostridium difficile –Associated Disease: Where Should We Start?. Clinical Infectious Diseases 43:5, 553-555
CrossRef413
Jennifer R. O'Connor, Dena Lyras, Kylie A. Farrow, Vicki Adams, David R. Powell, Jason Hinds, Jackie K. Cheung, Julian I. Rood. (2006) Construction and analysis of chromosomal Clostridium difficile mutants. Molecular Microbiology 61:5, 1335-1351
CrossRef414
David J. Weber. (2006) Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management. International Journal of Infectious Diseases 10, S17-S24
CrossRef415
R. Fuhr, R. Stahlmann. (2006) Gastrointestinale Nebenwirkungen von Antibiotika. Der Gastroenterologe 1:3, 173-179
CrossRef416
Nathan D. Nielsen, Blythe A. Layton, L. Clifford McDonald, Dale N. Gerding, Laura A. Liedtke, Larry J. Strausbaugh. (2006) Changing Epidemiology of Clostridium difficile-Associated Disease. Infectious Diseases in Clinical Practice 14:5, 296-302
CrossRef417
Thomas J. Louie, Jennifer Peppe, C. Kevin Watt, David Johnson, Rasheed Mohammed, Gordon Dow, Karl Weiss, Stuart Simon, Joseph F. John, Jr., Gary Garber, Scott Chasan‐Taber, David M. Davidson, . (2006) Tolevamer, a Novel Nonantibiotic Polymer, Compared with Vancomycin in the Treatment of Mild to Moderately Severe Clostridium difficile –Associated Diarrhea. Clinical Infectious Diseases 43:4, 411-420
CrossRef418
Daniel M. Musher, Nancy Logan, Richard J. Hamill, Herbert L. DuPont, Arnold Lentnek, Arvind Gupta, Jean‐Francois Rossignol. (2006) Nitazoxanide for the Treatment of Clostridium difficile Colitis. Clinical Infectious Diseases 43:4, 421-427
CrossRef419
John G. Bartlett. (2006) Editorial Commentary: New Drugs for Clostridium difficile Infection. Clinical Infectious Diseases 43:4, 428-431
CrossRef420
Hsun-Chin Chao, Chien-Chang Chen, Shih-Yen Chen, Cheng-Hsun Chiu. (2006) Bacterial enteric infections in children: etiology, clinical manifestations and antimicrobial therapy. Expert Review of Anti-infective Therapy 4:4, 629-638
CrossRef421
Mohammed Sebaihia, Brendan W Wren, Peter Mullany, Neil F Fairweather, Nigel Minton, Richard Stabler, Nicholas R Thomson, Adam P Roberts, Ana M Cerdeño-Tárraga, Hongmei Wang, Matthew TG Holden, Anne Wright, Carol Churcher, Michael A Quail, Stephen Baker, Nathalie Bason, Karen Brooks, Tracey Chillingworth, Ann Cronin, Paul Davis, Linda Dowd, Audrey Fraser, Theresa Feltwell, Zahra Hance, Simon Holroyd, Kay Jagels, Sharon Moule, Karen Mungall, Claire Price, Ester Rabbinowitsch, Sarah Sharp, Mark Simmonds, Kim Stevens, Louise Unwin, Sally Whithead, Bruno Dupuy, Gordon Dougan, Bart Barrell, Julian Parkhill. (2006) The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nature Genetics 38:7, 779-786
CrossRef422
A Singh, S. Clark. (2006) The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Disease 8:6, 528-529
CrossRef423
Cheleste M. Thorpe, Sherwood L. Gorbach. (2006) Update on Clostridium difficile. Current Treatment Options in Gastroenterology 9:3, 265-271
CrossRef424
G. E. Stein, E. J. C. Goldstein. (2006) Fluoroquinolones and Anaerobes. Clinical Infectious Diseases 42:11, 1598-1607
CrossRef425
Gregory A Coté, Alan L Buchman. (2006) Antibiotic-associated diarrhoea. Expert Opinion on Drug Safety 5:3, 361-372
CrossRef426
Betsy Todd. (2006) Clostridium Difficile:Familiar Pathogen, Changing Epidemiology. AJN, American Journal of Nursing 106:5, 33-36
CrossRef427
A. Y. Peleg, D. L. Paterson. (2006) Modifying Antibiotic Prescribing in Primary Care. Clinical Infectious Diseases 42:9, 1231-1233
CrossRef428
Ed J. Kuijper, Renate J. van den Berg, Sylvia Debast, Caroline E. Visser, Dick Veenendaal, Annet Troelstra, Tjallie van der Kooi, Susan van den Hof, Daan W. Notermans. (2006) Clostridium difficile Ribotype 027, Toxinotype III, the Netherlands. Emerging Infectious Diseases 12:5, 827-830
CrossRef429
Marin H. Kollef. (2006) The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance. Surgical Infections 7:2, 85-99
CrossRef430
A. SONNENBERG. (2006) Personal view: the paradox of runaway competitions in gastroenterology. Alimentary Pharmacology and Therapeutics 23:7, 871-878
CrossRef431
(2006) Epidemic Clostridium difficile. New England Journal of Medicine 354:11, 1199-1203
Full Text432
T. J. Louie. (2006) Treatment of First Recurrences of Clostridium difficile-Associated Disease: Waiting for New Treatment Options. Clinical Infectious Diseases 42:6, 765-767
CrossRef433
J. Pepin, N. Saheb, L. Lanthier. (2006) Reply to Weiss and to Beaulieu et al.. Clinical Infectious Diseases 42:5, 727-729
CrossRef434
Robert C Owens. (2006) Clostridium difficile –Associated Disease: An Emerging Threat to Patient Safety: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 26:3, 299-311
CrossRef435
Rebecca Doherty. (2006) Prevalence and treatment of Clostridium difficile-related disease. Nature Clinical Practice Gastroenterology & Hepatology 3:3, 124-125
CrossRef436
L. Clifford McDonald, Maria Owings, Daniel B. Jernigan. (2006) Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–20031. Emerging Infectious Diseases 12:3, 409-415
CrossRef437
D SNYDMAN. (2006) An Epidemic, Toxin Gene–Variant Strain of Clostridium difficileMcDonald LC, Killgore GE, Thompson A, et al (Centers for Disease Control and Prevention, Atlanta, Ga; Univ of Vermont, Burlington; Loyola Univ, Hines, III) N Engl J Med 353:2433–2441, 2005§. Yearbook of Medicine 2006, 113-115
CrossRef438
Bartlett, John G., Perl, Trish M., . (2005) The New Clostridium difficile — What Does It Mean?. New England Journal of Medicine 353:23, 2503-2505
Full Text439
Loo, Vivian G., Poirier, Louise, Miller, Mark A., Oughton, Matthew, Libman, Michael D., Michaud, Sophie, Bourgault, Anne-Marie, Nguyen, Tuyen, Frenette, Charles, Kelly, Mirabelle, Vibien, Anne, Brassard, Paul, Fenn, Susan, Dewar, Ken, Hudson, Thomas J., Horn, Ruth, René, Pierre, Monczak, Yury, Dascal, André, . (2005) A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile–Associated Diarrhea with High Morbidity and Mortality. New England Journal of Medicine 353:23, 2442-2449
Full Text
- Letters
